

Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of *Mycobacterium tuberculosis* Growth

Peter C. Ray, Margaret Huggett, Penelope A. Turner, Malcolm Taylor, Laura A. T. Cleghorn, Julie Early, Anuradha Kumar, Shilah A. Bonnett, Lindsay Flint, Douglas Joerss, James Johnson, Aaron Korkegian, Steven Mullen, Abraham L. Moure, Susan H. Davis, Dinakaran Murugesan, Michael Mathieson, Nicola Caldwell, Curtis A. Engelhart, Dirk Schnappinger, Ola Epemolu, Fabio Zuccotto, Jennifer Riley, Paul Scullion, Laste Stojanovski, Lisa Massoudi, Gregory T. Robertson, Anne J. Lenaerts, Gail Freiberg, Dale J. Kempf, Thierry Masquelin, Philip A. Hipskind, Joshua Odingo, Kevin D. Read, Simon R. Green,* Paul G. Wyatt,* and Tanya Parish*



Cite This: *ACS Omega* 2021, 6, 2284–2311



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: With the emergence of multi-drug-resistant strains of *Mycobacterium tuberculosis*, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular *in vitro* activity have been identified from phenotypic screening that appear to target MmpL3. However, the scaffolds are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. The spirocycle compound **3** was reported to target MmpL3 and displayed promising efficacy in a murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the hERG ion channel. Herein, the related spirocycles (**1–2**) are described, which were identified following phenotypic screening of the Eli Lilly corporate library against *M. tuberculosis*. The novel N-alkylated pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterion series, exemplified by lead **29**, with decreased HepG2 cytotoxicity as well as limited hERG ion channel inhibition. Strains with mutations in MmpL3 were resistant to **29**, and under replicating conditions, **29** demonstrated bactericidal activity against *M. tuberculosis*. Unfortunately, compound **29** had no efficacy in an acute model of TB infection; this was most likely due to the *in vivo* exposure remaining above the minimal inhibitory concentration for only a limited time.



INTRODUCTION

Mycobacterium tuberculosis,¹ the causative agent of tuberculosis (TB), can be fatal if not properly treated and disproportionately affects the poor in developing countries. In 2015, TB became the world's most deadly infectious disease, killing 1.4 million people (1.2 million HIV-negative and 0.3 million HIV-positive) in 2019.² The current 6 month treatment results in high default rates, increased transmission, and drug resistance.^{3–5} In order to reduce treatment length, TB treatments working through novel mechanisms are needed.^{6–8} However, identifying novel drugs remains a significant challenge, and high-quality leads are still urgently required.^{9,10}

Target-directed TB drug discovery programs have historically been largely unsuccessful in delivering high-quality late-stage leads.⁷ To address this issue, cell-based phenotypic screening became a focus for identifying active starting points. Many of the most potent phenotypic hits target membrane proteins such

as DprE1 and MmpL3 that are involved in cell wall biosynthesis.¹¹ MmpL3 is required for the export of trehalose monomycolates (TMM) to the periplasmic space and outer membrane of *M. tuberculosis*. A number of structurally diverse putative MmpL3 inhibitor series have been reported.^{12–29} Several of these series inhibit MmpL3-mediated TMM export but may also have pleiotropic effects targeting the proton motive force.¹³


The scaffolds of MmpL3 inhibitors are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and

Received: November 16, 2020

Accepted: December 21, 2020

Published: January 13, 2021



Table 1. *In Vitro* Profile of Early Hits against a Reported MmpL3 Inhibitor


	confirmed hit 1	confirmed hit 2	GSK-SPIRO 3	early lead 4
MIC ^a (μM)	0.22	0.14	0.083	0.11
MIC MmpL3 F255L mut. (μM)	31	16	1.7	2.6
hERG ^{b,c} IC ₅₀ (μM)	2.9 ^c	1.1 ^c	3.1 ^c	3.1 ^c
HepG2 ^d (μM)	36	32	20	38
LLE	4.5	4.5	3.0	4.3
SFI	5.2	5.5	7.1	5.4
kin. solubility (μM)	>250	>250	39	>250
MW	379	373	475	373
clog $D_{\text{pH}7.4}$	2.2	2.5	4.1	2.5
TPSA (\AA^2)	30	30	31	30
mouse Cl ^e (mL/min/g)	>50	>50	7.5	>50
human Cl ^f (mL/min/g)	ND	ND	1.7	4.6

^aMIC is the minimum concentration required to inhibit the growth of *M. tuberculosis* (H37Rv) in liquid culture. All MIC values are an average of at least two measurements. ^bhERG functional thallium flux inhibitory concentration (IC₅₀). ^chERG functional Q-patch inhibitory concentration (IC₅₀). ^dHepG2 inhibitory concentration (IC₅₀) is the concentration required to inhibit growth of HepG2 cells by 50%. ^eIntrinsic clearance (Cl) using CD1 mouse liver microsomes. ^fIntrinsic clearance (Cl) using pooled human liver microsomes. LLE is the lipophilic ligand efficiency; SFI is the solubility forecast index; TPSA is the total polar surface area. Estimations of clog $D_{\text{pH}7.4}$ and TPSA were calculated using StarDrop (<http://www.optibrium.com>).


several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. One particular spirocyclic series has been reported as a potential MmpL3 inhibitor following a phenotypic screen of the GSK library against *Mycobacterium bovis*.¹⁹ Although further exploration of this original hit identified compounds with excellent *in vivo* activity against *M. tuberculosis* (3), the series was discontinued because of concerns over safety related to the lipophilicity and basic nature of the scaffold.³⁰ Of note, the original authors highlighted that further exploration may be able to design around the series liabilities while retaining the remarkable *in vivo* potency³⁰

Herein, we report on a novel pyrazole spirocyclic amine series (1 and 2) with a putative MmpL3 mechanism of action that is structurally related to 3 (Table 1). The novel pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterionic series, with improved selectivity over both HepG2 cytotoxicity and hERG inhibition. The zwitterionic series retained potent *M. tuberculosis* whole cell activity, with large shifts against MmpL3 mutant strains. Unfortunately, the series representative with the best overall properties, 29, failed to show efficacy in an acute model of TB infection. As such, further work on this series was put on hold. We feel that the approach presented indicates useful insights into mechanisms for reduction of metabolism and hERG liabilities while highlighting the challenge within drug discovery of balancing these properties with potency.

RESULTS AND DISCUSSION


Structure–Activity Relationship. To identify novel anti-tubercular agents, an aerobic whole cell phenotypic screen was undertaken, evaluating the Eli Lilly corporate screening deck against *M. tuberculosis* strain H37Rv. One of the outcomes of this screen was the identification of a cluster of pyrazole-containing spirocyclic amine analogues; the spirocyclic portion of the molecule showed a clear structural resemblance to 3, a previously reported spirocycle series (Table 1).^{19,30} The initial hits had good anti-tubercular activity with a minimum inhibitory concentration (MIC) of 0.22 and 0.14 μM for 1 and 2, respectively (Table 1). As the original spirocycle compound was considered to be an MmpL3 inhibitor, we tested the activity of these two compounds against a strain containing a mutation in MmpL3 (F255L) and observed a large shift in the MIC confirming the likely on-target activity (Table 1).

According to the literature, 3 had not been developed further because “it suffered from a high clog P value, with the consequent potential liabilities for further development”.^{19,30,31} Compounds 1 and 2 offered an attractive alternative to 3 because the central aromatic ring in both was a pyrazole not a phenyl; this modification was predicted to reduce the clog $D_{\text{pH}7.4}$ by around 1 log unit. The reduced lipophilicity translated into a better solubility forecast index and *M. tuberculosis*-derived LLE,^{32–35} providing optimism for improving off-target liabilities, metabolic stability, as well as solubility profile. Unfortunately, as a result of the basic nature of the piperidine group, hERG inhibition remained an issue for 1 and 2;

Table 2. *In Vitro* Evaluation of Spirocycle Analogues

	R ₁	MIC ^a μM	clog D _{pH7.4}	hERG ^a IC ₅₀ μM	HepG2 ^a IC ₅₀ μM	mouse Cl _i ^a (mL/min/g)
4	phenyl	0.11	2.5	3.1 ^a	38	>50
5	no group	4.7	1.7	>30 ^a		28
6	6-fluorophenyl	0.16	2.7	3.5 ^a	48	>50
7	7-fluorophenyl	0.12	2.7	4.7 ^a	32	>50
8	6,7-difluorophenyl	0.69	2.8	1.8 ^a	14	>50
9	6-CF ₃ -phenyl	>20	3.1	0.8 ^a	7	9
10	7,8-difluorophenyl	2.5	2.8	1.7 ^a	16	>50

^aSee Table 1 for explanation.

Table 3. *In Vitro* Evaluation of Spirocycle Analogues

	R ₂	R ₃	MIC ^a (μM)	clog D _{pH7.4}	hERG ^a IC ₅₀ (μM)	HepG2 ^a IC ₅₀ (μM)	mouse Cl _i ^a (mL/min/g)
11	phenyl	OMe	0.12	2.5	2.1 ^a	23	>50
12	phenyl	CyPr	0.10	3.0	2.2 ^a	22	>50
13	phenyl	CHF ₂	0.20	3.1	3.6 ^a	15	>50
14	phenyl	CF ₃	0.09	3.1	4.7 ^a	30	>50
15	4-(hydroxymethyl) phenyl	Me	1.5	2.0	5.0 ^a	>50	8.5
16	4-methylphenyl	Me	0.08	2.6	2.5 ^a	11	>50
17	4-(trifluoromethoxy) phenyl	Me	0.36	3.4	1.9 ^a	8.6	7
18	6-methoxy pyridin-3-yl	Me	0.37	2.0	3.5 ^a	>50	44
19	6-(difluoromethoxy)-pyridin-3-yl	Me	0.21	2.5	0.52 ^a	18	25
20	6-(trifluoromethyl) pyridin-3-yl	Me	0.51	2.6	2.7 ^a	42	10
21	2-benzoic acid	Me	>20	0.6	>30 ^a	>50	<0.5
22	3-benzoic acid	Me	3.7	0.5	10.2 ^a	>50	1.6
23	4-benzoic acid	Me	4.8	0.6	>30 ^a	>50	0.5
24	4-benzoic acid	Et	0.77	0.9	>30 ^a	>50	1.1
25	4-benzoic acid	iPr	3.8	1.4	>30 ^a	>50	1.2
26	4-benzoic acid	tBu	5.5	1.3	>30 ^a	>50	1.1
27	4-benzoic acid	CHF ₂	1.4	1.3	>30 ^a	>50	0.7
28	4-benzoic acid	CF ₃	0.65	1.5	>30 ^a	>50	1
29	4-benzoic acid	CyPr	0.66	1.2	>30 ^a	>50	1.1
30	4-benzoic acid	CyBu	1.8	1.5	>30 ^a	>50	1.6
31	4-benzoic acid	OMe	1.9	0.6	>30 ^a	>50	1.3
32	4-benzoic acid	OEt	0.53	0.9	>30 ^a	>50	3.8
33	4-benzoic acid	N-pyrrolidino-	13	1.3		>50	1.5
34	4-benzoic acid	N-morpholino-	>20	1.3		>50	<0.5

^aSee Table 1 for explanation.

moreover, despite the lower clog $D_{pH7.4}$, both showed unexpectedly high mouse microsomal clearance.

Initial emphasis for expansion of the confirmed hits 1 and 2 was placed on understanding the scope for improving hERG channel inhibition and microsomal stability. The pyrazole of 1

and the spirocycle of 2 were combined to afford 4, which showed marginally improved selectivity over the hERG channel, although the mouse microsomal clearance remained high (Tables 1 and 2). In addition, the human microsomal metabolic stability was higher for 4 than the published molecule

Table 4. Activity against *M. tuberculosis* Clinical Strains of Different Lineage and Resistance^a

	MIC ₉₀ (μM)						
	H37Rv	N0157 L1	N0052 L2	N0004 L3	N0136 L4	INH-R2	RIF-R2
23	5.1	>50	7.3	24	9.6	8.6	13
29	0.78	2.8	2.2	5.2	2.4	0.37	0.76
rifampicin	0.01	0.01	0.01	0.01	0.01	0.01	>50
isoniazid	ND	ND	ND	ND	ND	>200	0.58

^aMIC is the minimum concentration required to inhibit the growth of *M. tuberculosis* (H37Rv) in liquid culture L1 is TB lineage 1 and so forth.




Figure 1. Kill kinetics for 29 against replicating and nonreplicating *M. tuberculosis*. Bacterial viability in the presence of compound was determined by cfu over 28 days (A) under replicating conditions and (B) under nonreplicating conditions. The dashed lines represent the upper and lower limits of detection.

3, although both values were lower than the equivalent mouse data. As a first step to attempt to reduce metabolism of 4, a mouse microsomal metabolite identification study was carried out to evaluate why the pyrazole series had worse microsomal stability than 3 despite a lower $clog D_{pH7.4}$ (Table 1). This showed that 4 was metabolized rapidly to four main metabolites primarily involving hydroxylation. After a 3 min incubation in mouse microsomes, only 29% of the parent ion remained, while 61% of the detectable ions were associated with three metabolites that resulted from hydroxylation associated with regions of the molecule around the spirocycle group (Table S1; Figures S1 and S2). Because phenyl groups are known to be prone to hydroxylation, which can be prevented by fluorination,³⁶ the phenyl substituent on the spirocycle was replaced by a series of different fluoro-substituted phenyl groups (Table 2). Unfortunately, compounds that retained good MIC activity remained very unstable in mouse microsomes, while the compounds with improved metabolic stability had significantly decreased potency (Table 2).

To examine the metabolic stability further, isoform-specific cytochrome P450 studies were carried out on 4, evaluating CYP3A4 and CYP2D6 as the two most abundant human CYP450 enzymes. Pyrazole 4 was more rapidly cleared by CYP2D6 bacosomes (0.34 min^{-1}) than CYP3A4 bacosomes (0.07 min^{-1}). As the CYP2D6-active site is known to be smaller in comparison to CYP3A4,³⁷ it was proposed that increasing the size of substituents on either the 5-methyl pyrazole or the phenyl in 4 could potentially lead to a decrease in CYP2D6 metabolism and thereby improve the metabolic stability to be more in line with the larger compound 3.

To test the above hypothesis, the structure–activity relationship (SAR) around the methyl and phenyl substituents was expanded. Initial modifications to the 5-methyl pyrazole had little effect on MIC, hERG channel inhibition, or metabolic stability (11–14), and so further exploration of this substituent

was put on hold. For the phenyl substituted compounds 15–17, there was a trend toward improved metabolic stability, in particular with the bulky OCF_3 blocking group of 17 despite it having a high $clog D_{pH7.4}$ (Table 3). In an attempt to reduce or maintain as low a $clog D_{pH7.4}$ as possible, the SAR around a 1-pyridyl substituent was explored. For the pyridyl-substituted compounds 18–20, again there was a trend toward improved metabolic stability, in particular with bulkier and more lipophilic groups such as the CF_3 in 20 (Table 3).

As an alternative phenyl substitution, the addition of a carboxylic acid group was explored (Table 3). Such a modification adds bulk, introduces polarity, and the presence of a zwitterion has been shown previously to overcome hERG channel inhibition.³⁸ While the ortho-acid 21 was not tolerated, the modest *M. tuberculosis* whole cell activity of 22 and 23 was encouraging especially because the para-acid 23 showed a dramatic improvement in the compound's liabilities including hERG channel inhibition, mouse metabolic stability, and HepG2 cytotoxicity. Although the overall properties of 23 were an improvement on 4, this came at a significant reduction in antibacterial potency (~ 40 fold). To continue optimization of 23, we reassessed modifications of the 5-methyl pyrazole as these had been tolerated previously on 4. In general, substitutions 29–34 were well tolerated, apart from cyclic amines 33 and 34, with good profiles in relation to hERG inhibition, mouse metabolic stability, and HepG2 cytotoxicity. Substituted alkyl as well as fluoroalkyl resulted in notable improvements in the whole cell potency for cyclopropyl 29, trifluoromethyl 28, ethyl 24, and ethoxy 32 (Table 3).

Biological Profiling. Compound 29 was not cytotoxic to HepG2 cells, grown in either glucose or galactose media, nor the THP-1 macrophage-like cell line (data not shown). 29 had good potency against intracellular bacteria in THP-1 cells [$\text{IC}_{50} = 1.5 \pm 1.3$]. Compound 29 was also shown to retain good activity against clinical samples from the four main lineages and




Figure 2. Decreased MmpL3 expression results in hypersensitivity to the spirocycle series. Removal of anhydrotetracycline (atc) results in transcriptional repression of *mmpL3*. Growth in the presence of a negative control ethambutol (A) and a positive control SQ109 (B) as well as representative series compound, 4 (C) and 23 (D) are recorded relative to DMSO-treated samples. Data are representative of two independent experiments.

strains containing resistance mutations to either isoniazid or rifampicin (Table 4).

Minimum bactericidal concentration (MBC) and kill kinetics were evaluated under both aerobic (replicating) and starvation (nonreplicating) conditions. Under replicating conditions, **29** showed concentration-dependent kill of *M. tuberculosis* with an MBC of 3 μM (Figure 1A). At later stages, outgrowth was observed because of either compound instability over long incubation periods or the appearance of resistant mutants. Under nonreplicating conditions, **29** showed no bactericidal effect against *M. tuberculosis* (Figure 1B).

Compound **29** showed a 10-fold decrease in activity against the MmpL3_{F255L} strain of *M. tuberculosis*, indicating that it retained an MmpL3-related mechanism of action. An impact on this pathway was also indicated using a hypomorph strain (P606-5C-mmpL3) that underexpresses MmpL3 when grown in the absence of anhydrotetracycline (Figure 2). Initially, it was confirmed that SQ109, a known inhibitor of MmpL3, was more active against the hypomorph strain with a four-fold improvement in MIC₅₀, while ethambutol, a cell wall inhibitor targeting a different pathway (arabinosyl transferases), was equally effective against both the wild-type and hypomorph strains. We tested two representatives from the series (**4** and **23**); both showed significant shifts in potency, with the MmpL3 hypomorph being at least eight-fold more sensitive. These data support the conclusion that, as shown in the literature for **3**, the series works through an MmpL3-related mechanism.

In Vivo Analysis. Based on the hit to lead SAR, representative compound **29** was selected for follow-up. A fluorinated derivative, **35**, was also prepared as such modifications had been shown previously (Table 2) to not have a detrimental effect on MIC activity but could potentially improve metabolic stability and *in vivo* exposure. As expected, **35** had a similar MIC activity to **29** (Table 5). Although there was no significant change in metabolic stability, neither mouse

Table 5. Biology and ADME/PK Profiles for Selected Best Molecules

	29	35
MIC ^a μM	0.66	0.79
hERG ^a IC ₅₀ μM	>30 ^a	10 ^a
HepG2 ^a μM	>50	>50
clog <i>D</i> _{pH7.4}	1.2	1.4
microsomal Cl ^a mL/min/g	1.1	0.9
human micro Cl ^a mL/min/g	0.6	0.5
C57 mouse PK at 3 mg/kg iv and 10 mg/kg po		
C _{max} po (ng/mL)	164	294
T _{1/2} (h)	2	2.6
AUC _{0–24} po (ng·min/mL)	20,728	36,486
Cl _b (mL/min/kg)	56	53
Vd _{ss} (L/kg)	2	3
% F	12	19

^aSee Table 1 for explanation.

nor human, the fluorination did result in an unexpected increase in activity against the hERG ion channel. The *in vivo* exposure of both compounds was evaluated in female C57BL/6 mice (*n* = 3/dose level) (Table 5). Both compounds had moderate *in vivo* blood clearance, moderate volume of distribution, moderate half-life, and low bioavailability. Although the

exposure of **35** was greater than **29**, it was not substantially improved enough to make it worthwhile to risk the increase in hERG channel inhibition. Therefore, further work focused on **29**. As the initial preliminary pharmacokinetic analysis was done on the free-base form of the molecule, a hydrochloride salt form of **29** was prepared and evaluated at higher doses to determine whether the compound was suitable for an *in vivo* efficacy assessment. The HCl salt of **29** was dosed at 200 and 400 mg/kg in 1% carboxymethylcellulose (CMC) generating C_{\max} values of 22,266 and 85,278 ng/mL, respectively. Moreover, at both the 200 and 400 mg/kg doses, the exposure, both total and free (plasma $F_u = 0.2$), was above the reported MIC (0.66 $\mu\text{M}/292$ ng/mL) for >6 h.

Based on the results from the PK studies, **29** was assessed in an acute mouse model of TB infection using Balb/c mice in a direct comparison with the previously reported compound **3**.³⁰ As expected, **3** was very active in the study promoting a >2.5 \log_{10} reduction in colony forming units (CFUs), reducing lung burdens in infected mice near to or below the limit of detection (Figure 3). This was similar to the control drug rifampicin given




Figure 3. Efficacy in a mouse model of acute TB infection. BALB/c mice were infected with *M. tuberculosis* H37Rv via a low-dose aerosol exposure. Treatment was started 7 days post-aerosol and continued for 12 consecutive days. Drugs were administered once daily by oral gavage at 100 mg/kg (**3**) and 300 mg/kg (**29**).

at a dose of 20 mg/kg (Figure 3). In contrast, **29** showed no appreciable reduction in lung CFUs relative to the untreated control in this experiment. Plasma samples for PK from these infected animals were taken during steady state at 1 and 24 h after dosing. Although both compounds showed free plasma concentrations well above MIC at 1 h post-dosing, only **3** remained above MIC for the full 24 h period. Thus, one potential explanation for the difference in efficacy was inadequate drug exposure above MIC for **29** compared to **3**.

CHEMISTRY

Synthetic Routes. Synthesis of related spirocyclic amines has been previously reported.^{19,39} The general synthetic routes employed for the synthesis of pyrazole containing spirocyclic amines are shown below (Scheme 1). The appropriately substituted R1 aryls or heteroaryl were reacted with 1-[(4-methoxyphenyl)methyl]piperidin-4-one to form **48**, which was then deprotected to form amine **49**. An alternative route involved reacting the appropriately substituted R1 aryls or heteroaryl with the protected piperidin-4-one to form diols **40–43**. Cyclic dehydration afforded **44–47**, which were deprotected to afford amines **50–53**. Substituted pyrazole aldehydes **70–77** were prepared from the esters **63–69** (Scheme S1 in Supporting Information) by reduction to the alcohol and then oxidation to the aldehydes. R2- and R3-substituted pyrazole esters **63–69** were prepared in three main ways: from R3-substituted pyrazole **60**, using copper-mediated


coupling of suitable R2 boronic acids, by cyclo-dehydration of ethyl 4-(R3)-2,4-dioxo-butanoates **55–59** with R2-substituted hydrazines, and by reaction of dimethyl but-2-ynedioate with R2-substituted hydrazines. In the final step, reductive amination with appropriate R2- and R3-substituted pyrazole aldehydes **70–77** afforded target compounds **1–14**, **17**, **18**, **20**, and **21**. Further Chan–Lam coupling of the NH pyrazole **78** with appropriate boronic acids afforded target compounds **15**, **16**, and **19**.

For compounds containing a carboxylic acid moiety on the phenyl ring attached to the pyrazole core, a different approach was needed. For these compounds, some could be synthesized by carrying the carboxylic acid through the synthesis protected as an oxazoline (Scheme 2) and some by a late-stage conversion from the bromide (Scheme 3). Carboxylic acid substituted phenyl hydrazines could be reacted with suitable triketone compounds to afford R3-substituted pyrazole esters **87**, **88**, and **90–92**. Because of carrying an ester in these molecules, ester protection of the acid was not a plausible route at this stage, and so to synthetically distinguish the different functional groups, the acids were protected as oxazolines. Amide coupling with ethanolamine followed by chlorination and cyclization easily provided oxazolines **93–98**, which could then be carried through the synthesis without problem. Reduction to aldehydes **99–104** as before followed by reductive amination to **105–109** and simple deprotection with 2 M HCl afforded the target compounds **22**, **23**, and **26–28**. Compound **24** followed the majority of this route; however, the carboxylate **95** was synthesized via reaction of 4-aminobenzoic acid with ethyl 2-chloro-3-oxo-butanoate and subsequent cyclization to the pyrazole. Alternatively, when the substituted phenyl hydrazine could be reacted with R3-substituted diethoxy diketo compounds **81–83**, then only one synthetic step was needed to afford compounds **25**, **29**, **30**, and **35**.

The carboxylic acid compounds could also be realized from the bromides. Reaction of 4-bromophenylhydrazines with dimethyl but-2-ynedioate afforded pyrazole **110**. Where the desired R group was an alkoxy group, the hydroxyl moiety could be simply alkylated. Where R3 was an amine, this was introduced via a Vilsmeier reaction, followed by S_NAr and removal of the aldehyde, to form compounds **114–117**. As in the previous schemes, reduction to aldehydes **118–121** followed by reductive amination afforded spirocyclic amino pyrazoles **122–125**. In order to convert the bromide to carboxylic acid, compounds **122–125** were carbonylated using *N*-formylsaccharin as a source of carbon monoxide, which is slowly released *in situ* as described in the literature.⁴⁰ The acyl fluoride formed in the reaction as a result of the caesium fluoride base was quenched with H_2O to form the final target compounds **31–34**. For all the compounds discussed in this report, no alerts were found when they were processed through a PAINS filter.

CONCLUSIONS

Following on from the previous publication of a spirocycle series with potent inhibition of *M. tuberculosis* but limited by safety concerns,³⁰ the optimization of a related but novel pyrazole spirocyclic amine is described. This report identified a zwitterionic series, exemplified by lead **29** that when compared to the original series, **3** had improved selectivity over HepG2, as well as reduced hERG channel inhibition. As with the original series, **29** was a putative MmpL3 inhibitor as large shifts against MmpL3 mutant strains were observed. Although **29** has a better

Scheme 1. General Synthetic Routes for the Synthesis of Compounds 1–21^a

^aReagents and conditions: (i) BH₃·THF, THF, 100 °C, and 1 h; (ii) *n*BuLi, THF, −78 °C, 1 h, then *tert*-butyl 4-oxopiperidine-1-carboxylate −78 °C—rt, and 18 h; (iii) MeSO₂Cl, Et₃N, DCM, reflux, and 1.5 h; (iv) TFA, DCM, and 18 h; (v) 1-[(4-methoxyphenyl)methyl]piperidin-4-one, MeSO₃H, PhMe, reflux, Dean–Stark, and 18 h; (vi) 1-chloroethyl carbonochloridate, DCM, 0 °C then MeOH, reflux, and 1 h; (vii) DIPEA, DMSO, rt, and 18 h; (viii) AcOH or EtOH, reflux, and 2 h; (ix) R₂B(OH)₂, Cu(OAc)₂, pyridine, DCM, and 2 h; (x) Et₂O, rt, 1 h, then NaOMe, MeOH, rt, 18 h, then H₂SO₄, MeOH, reflux, and 48 h; (xi) PPh₃, DIAD, THF, MeOH, rt, and 18 h; (xii) DIBAL, DCM, −78 °C—rt, then MnO₂, DCM, rt, and 48 h; (xiii) AcOH, DCM, then NaBH(OAc)₃, and 18 h; (xiv) R₄B(OH)₂, Cu(OAc)₂, pyridine, DCM, rt, and 3–18 h.


selectivity profile than the earlier molecules, this came at the expense of reduced potency; as such, while **3** had excellent activity in an acute *in vivo* model of TB infection, **29** was found not to be efficacious in the same model. The lack of efficacy of **29** was hypothesized to be as a result of the need for improved *in vivo* exposure to ensure maximum coverage above the MIC. Thus, despite the original authors highlighting the possibility of eliminating series liabilities while retaining the remarkable *in vivo* potency,³⁰ given the complexity of balancing metabolic stability and hERG channel inhibition with MIC activity for this series, no further work was planned to try and improve exposure.

EXPERIMENTAL SECTION

Determination of MIC. MICs were determined against *M. tuberculosis* H37Rv (ATCC 25618) and mutant strains grown

in Middlebrook 7H9 medium containing 10% v/v OADC (oleic acid, albumin, dextrose, and catalase) supplement (Becton Dickinson) and 0.05% w/v Tween 80 (7H9-Tw-OADC) under aerobic conditions as previously described. Bacterial growth was measured after 5 days of incubation at 37 °C.⁴¹

MmpL3 Hypomorph. Wild-type H37Rv and P606-5C (in which the native copy of *mmpL3* was replaced with *kanR* and a tetracycline-regulated copy of *mmpL3* was inserted at the att-L5 site and also contains *zeoR*) were each cultured in 10 mL of Middlebrook 7H9 [with kanamycin and zeocin at 25 μg/mL and anhydrotetracycline (atc) at 500 ng/mL for the mutant strain] supplemented with 0.2% (v/v) glycerol, 0.05% (v/v) tyloxapol, and ADNaCl (0.5% [w/v] BSA, 0.2% [w/v] dextrose, and 0.85% [w/v] NaCl) in a 25 cm² tissue culture flask with a vented cap. After approximately 7 days at 37 °C and 5% CO₂ in

Scheme 2. General Synthetic Routes for the Synthesis of Compounds 22–30 and 35^a

^aReagents and conditions: (i) EtOH, AcOH, reflux, and 1–18 h; (ii) spiro[isochromane-1,4'-piperidine], AcOH, DCM, then NaBH(OAc)₃, and 18 h; (iii) EtOH, H₂O, 35 °C, and 18 h; (iv) SOCl₂, pyridine, 50 °C, 2 h then ethanolamine, DCM, rt, 3 h, then SOCl₂, rt, and 18 h; (v) NaH, THF, 0 °C, and 3 h; (vi) DIBAL, DCM, -78 °C—rt, then MnO₂, DCM, rt, and 48 h; (vii) spiro[isochromane-1,4'-piperidine], AcOH, DCM, then NaBH(OAc)₃, 18 h; and (viii) 3 M HCl, 100 °C, and 18 h.

a humidified incubator, growing to mid-log to late-log phase, each of the cultures was washed with fresh 7H9 and suspended to an OD₅₈₀ of 0.05 in 30 mL of 7H9 (with selection antibiotics for the mutant but without atc to deplete the levels of MmpL3) in a 75 cm² tissue culture flask with a vented cap and was incubated for further 14 days with a passage to OD₅₈₀ = 0.05 in 30 mL of 7H9 at day 7. Bacteria were then washed once in fresh medium and single-cell suspensions were prepared to a final OD₅₈₀ of 0.01 in 7H9. Compounds were solubilized in DMSO and dispensed into 384-well plates using an HP D300e Digital Dispenser as 11-point, 4-fold dilution series in triplicate. DMSO at a final concentration of 1% was used as no-drug control. In all, 50 μL of single-cell suspension was pipetted to each well and cultures were incubated for 7–14 d at 37 °C in the same conditions as mentioned above. Final OD₅₈₀ values were normalized to no-drug control.


M. tuberculosis Kill Kinetics. For replicating conditions, late-log phase bacteria were exposed to compounds in 5 mL medium under aerobic conditions in standing cultures over 21 days. For starvation conditions, bacteria were resuspended in phosphate-buffered saline plus 0.05% tyloxapol for 14 days before compound addition. Viable bacteria were measured by plating serial dilutions and counting cfus after 4 weeks.

Intracellular Activity. THP-1 cells were propagated in RPMI-1640 supplemented with 10% FBS, 2 mM glutagro, and 1 mM sodium pyruvate medium in a humidified atmosphere of 37 °C with 5% CO₂. Cells were differentiated with 80 nM PMA treatment overnight and infected with *M. tuberculosis* (H37Rv LuxG13) at a multiplicity of infection of 1. Infected cells were

harvested with Accutase, 5 mM EDTA, washed twice with PBS, seeded into 96-well plates at 4 × 10⁴ cells per well, and incubated for 24 h. Compounds were added as a 10-point three-fold serial dilution (0.5% DMSO final concentration). Bacterial viability was measured after 72 h. Growth inhibition curves were fitted using the Levenberg–Marquardt algorithm. IC₅₀ and IC₉₀ were defined as the compound concentrations that inhibited 50 or 90% of the intracellular growth, respectively.

THP-1 Cytotoxicity. THP-1 cells were propagated, differentiated into macrophages, and harvested as described above and seeded into 96-well plates at 4 × 10⁴ cells per well for 24 h. Compounds were added as a 10-point three-fold serial dilutions (0.5% DMSO final concentration). Viability was measured after 72 h using CellTiter-Glo. Growth inhibition curves were fitted using the Levenberg–Marquardt algorithm. IC₅₀ was defined as the compound concentration that reduced cell viability by 50%.

HepG2 Cytotoxicity. Compound dilution curves were plated directly using a Labcyte Echo 550 acoustic dispenser (125 nL) in 384-well white clear-bottomed plates (Greiner). HepG2 cells (ECACC 85011430) were cultured in minimum essential medium (supplemented with glutamax) with 10% FCS and plated (25 μL) using a WellMate dispenser (1 × 10⁵ per well) and incubated for 72 h. Doxorubicin was used as a positive control drug. Resazurin was then added to each well at a final concentration of 45 μM, and fluorescence was measured using PHERAstar LS (BMG Labtech) after 4 h of further incubation (excitation of 528 nm and emission of 590 nm). Raw data were normalized to controls and expressed as %

Scheme 3. General Synthetic Routes for the Synthesis of Compounds 31–34^a

^aReagents and conditions: (i) POCl₃, DMF, 100 °C, and 2 h; (ii) R₃H, K₂CO₃, DMF, microwave, 120 °C, and 1 h; (iii) pT₃OH, MeOH, microwave, 120 °C, and 1 h; (iv) R₃I, K₂CO₃, DMF, 0 °C–rt, and 2 h; (v) DIBAL, DCM, –78 °C–rt, then MnO₂, DCM, rt, and 48 h; (vi) AcOH, DCM, then NaBH(OAc)₃, and 18 h; and (vii) *N*-formylsaccharin, Pd(OAc)₂, Xantphos, KF, DMF, 80 °C, and 18 h then H₂O.

growth. IC₅₀ was defined as the compound concentration that resulted in 50% inhibition.

Intrinsic Clearance (CLi) Experiments. Test compound (0.5 μM) was incubated with female CD1 mouse liver microsomes (Xenotech LLC) or pooled human liver microsomes (Life Technologies) at a final concentration of 0.5 mg/mL 50 mM potassium phosphate buffer, pH 7.4, and the reaction started with addition of excess NADPH (8 mg/mL 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, then at 3, 6, 9, 15, and 30 min, an aliquot (50 μL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to stop the reaction. Internal standard was added to all samples, the samples were centrifuged to sediment precipitated protein, and the plates were then sealed prior to ultra-performance liquid chromatography–mass spectrometry (UPLC/MS/MS) analysis using a Quattro Premier XE (Waters Corporation, USA). XLfit (IDBS, UK) was used to calculate the exponential decay and consequently the rate constant (*k*) from the ratio of peak area of test compound to internal standard at each time point. The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following calculation

$$\text{CLi (mL/min / g liver)} \\ = k \times V \times \text{microsomal protein yield}$$

where *V* (mL/mg protein) is the incubation volume/mg protein added and microsomal protein yield is taken as 52.5 mg protein/g liver. Verapamil (0.5 μM) was used as a positive control to confirm acceptable assay performance.

Isoform-specific metabolism studies were performed as mentioned above except that mouse liver microsomes were replaced with incubation mixtures containing EasyCYP bacosomes (50 pmol/mL, 0.5 mg/mL Cypex).

Aqueous Solubility. The aqueous solubility of the test compounds was measured using laser nephelometry. Compounds were subject to serial dilution from 10 to 0.5 mM in DMSO. An aliquot was then mixed with Milli-Q water to obtain an aqueous dilution plate with a final concentration range of 250–12 μM with a final DMSO concentration of 2.5%. Triplicate aliquots were transferred to a flat-bottomed polystyrene plate, which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against compound concentration using a segmental regression fit, with the point of inflection being quoted as the compound's aqueous solubility (μM).

Mouse Pharmacokinetics. The test compound was dosed as a bolus solution intravenously or dosed orally by gavage to female C57 black mice (*n* = 3/dose level). Blood samples were collected from each mouse tail vein at predetermined time points post-dose, mixed with two volumes of distilled water, and stored frozen until UPLC/MS/MS analysis. Pharmacokinetic parameters were derived from the blood concentration time curve using PK Solutions software v2.0 (Summit Research Services, USA). All regulated procedures, at the University of Dundee, on living animals were carried out under the authority of a project license issued by the Home Office under the

Animals (Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/2010/63).

hERG Assays. These were performed as previously described^{42,43} in brief: thallium flux high-throughput testing, hERG functional activity was measured in an inducible hERG T-RExTM-CHO Cell line (Thermo Fisher #K1237) using thallium influx as a surrogate indicator of potassium ion channel activity. Thallium enhances the fluorescent signal of BTC-AM dye (Thermo Fisher #B6791). Cells were loaded with the dye for 90 min in a low potassium buffer, dye removed, and compound added to the cells in a high potassium buffer in a 6 pt. dose response. After 30 min of compound incubation, channel activity was recorded upon addition of thallium buffer using a Tetra plate reader. The slope of the kinetic read was used to calculate channel activity. For QPatch testing, HEK-293 cells stably transfected with the hERG channel were tested in either QPatch (Sophion) or PatchXpress (Molecular Devices), automated planar patch-clamp systems. The cells were added to each chamber, negative pressure was applied to obtain intracellular access, and cells were exposed to either three or four ascending concentrations of drug. hERG tail current was measured as the difference in amplitude between a -50 mV pre-pulse and the end of a five-second test pulse to -50 mV, preceded by a depolarizing pulse ($+20$ mV). The hERG IC₅₀ value was determined from tail current.

Murine Model of Acute TB Infection. All infections were performed at Colorado State University in a certified ABSL3 facility in accordance with the guidelines of the Colorado State University Institutional Animal Care and Use Committee. Six to eight week old female specific pathogen-free BALB/c mice were purchased from Charles River Laboratories (Wilmington, MA). The mice were infected with *M. tuberculosis* H37Rv via a low-dose aerosol exposure in a Glas-Col aerosol generation device (Glas-Col Inc., Terre Haute, IN).⁴⁴ Each treatment group consisted of six mice. **29** was formulated in 1% CMC (Sigma). **3** was formulated in 1% MC (Sigma). Rifampin was prepared using a mortar and pestle in sterile water. The treatment was started 7 days post-aerosol and continued for 12 consecutive days. Drugs were administered by oral gavage in a 0.2 mL volume at 300, 100, and 20 mg/kg for **29**, **3**, and rifampicin, respectively. For endpoint analysis, mice were euthanized 3 days following the end of treatment and lungs were collected. The left lung lobe (1/3rd of the lung by weight) was homogenized for enumeration of cfu by plating dilutions of the organ homogenates on Middlebrook 7H11 medium supplemented with 10% (v/v) OADC, 0.01 mg/mL of cycloheximide, and 0.05 mg/mL of carbenicillin. The data were expressed as mean log 10 cfu \pm the standard error of the mean for each group. Statistical analysis was done by one-way analysis of variance with Dunnett's post-test to control for multiple comparisons (SigmaPlot, San Jose, CA). Values were considered significant at the 95% confidence level.

General Chemistry Methods. Chemicals and solvents were purchased from commercial vendors and used as received unless otherwise stated. Dry solvents were purchased in Sure Seal bottles stored over molecular sieves. Unless otherwise stated herein, reactions have not been optimized. Analytical thin-layer chromatography (TLC) was performed on precoated TLC plates (Kieselgel 60 F254, BDH). Developed plates were air-dried and analyzed under a UV lamp (UV 254/365 nm) and/or KMnO₄ was used for visualization. Flash chromatography was performed using Combiflash Companion Rf (Teledyne ISCO) and prepacked silica gel columns purchased

from Grace Davison Discovery Science or SiliCycle. Mass-directed preparative HPLC separations were performed using a Waters HPLC (2545 binary gradient pumps, S15 HPLC make-up pump, and 2767 sample manager) connected to a Waters 2998 photodiode array and a Waters 3100 mass detector. Preparative HPLC separations were performed with a Gilson HPLC (321 pumps, 819 injection module, and 215 liquid handler/injector) connected to a Gilson 155 UV/vis detector. On both instruments, HPLC chromatographic separations were conducted using Waters XBridge C18 columns, 19 mm \times 100 mm, 5 μ m particle size, using 0.1% ammonia in water (solvent A) and acetonitrile (solvent B) as the mobile phase. ¹H NMR spectra were recorded on a Bruker ADVANCE II 500 or 400 spectrometer operating at 500 and 400 MHz (unless otherwise stated) using CDCl₃, DMSO-*d*₆, or CD₃OD solutions. Chemical shifts (δ) are expressed in ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), multiplet (m), broadened (br), or a combination thereof. Coupling constants (*J*) are quoted to the nearest 0.1 Hertz (Hz). Low-resolution electrospray mass spectra were recorded on a Bruker Daltonics MicroTOF mass spectrometer run in the positive mode. High-resolution mass spectroscopy (HRMS) was performed using a Bruker Daltonics MicroToF mass spectrometer. LC-MS analysis and chromatographic separation were conducted with either a Bruker Daltonics MicroTOF mass spectrometer connected to an Agilent diode array detector or a Thermo Dionex Ultimate 3000 RSLC system with a diode array detector, the column used was a Waters XBridge column (50 mm \times 2.1 mm, 3.5 μ m particle size), and the compounds were eluted with a gradient of 5–95% acetonitrile/water + 0.1% ammonia or with an Advion Expression Mass Spectrometer connected to a Thermo Dionex Ultimate 3000 HPLC with a diode array detector, the column used was a Waters XBridge column (50 mm \times 2.1 mm, 3.5 μ m particle size), or a Waters X-select column (30 mm \times 2.1 mm, 2.5 μ m particle size) with a gradient of 5–90% acetonitrile/water + 0.1% formic acid. All final compounds showed chemical purity of $\geq 95\%$ as determined by the UV chromatogram (190–450 nm) obtained by LC-MS analysis.

General Method 1. Respective spirocyclic amines (1 equiv) and aldehydes (1 equiv) were combined in DCM (0.1–0.2 M), one drop of acetic acid was added, and the mixtures were stirred at rt for 1 h. Sodium triacetoxyborohydride (1.5–2 equiv) was added and the mixtures were stirred at rt for 18 h. The mixtures were washed with NaHCO₃ (saturated solution) and the organics were concentrated *in vacuo*. The crude materials were purified by preparative HPLC (XBridge column, 0.1% NH₄OH modifier) and the fractions were concentrated *in vacuo* to afford the titled compounds.

General Method 2. Respective pyrazoles (1 equiv), boronic acids (2 equiv), and copper acetate (1.5 equiv) were combined in DCM (0.1 M) and pyridine (20 equiv) and stirred at rt for 3–18 h. The solvents were removed *in vacuo* and the crude products were purified by either flash chromatography (0–100% EtOAc in heptane) or preparative HPLC (XBridge column, 0.1% NH₄OH modifier), and the fractions were concentrated *in vacuo* to afford the titled compounds.

General Method 3a. Respective hydrazines (1 equiv) and 2,4-dioxo-butanoates (1 equiv) were dissolved in EtOH (0.15 M) and heated to reflux for 1–3 h. The solvent was removed *in vacuo* and H₂O was added. The products were extracted with EtOAc and concentrated *in vacuo*, and the resulting crude

products were purified by flash chromatography (5–50% EtOAc in heptane) to afford the titled compounds.

General Method 3b. Respective hydrazines or hydrazine hydrochlorides (1 equiv) and 2,4-dioxo-butanoates (1 equiv) were dissolved in AcOH (0.7 M), and the reaction mixtures were heated to reflux for 2 h and then allowed to cool to rt. The solvent was removed *in vacuo*, and the residue was partitioned between DCM and 1 M NaOH and then passed through a hydrophobic frit. The crude materials were purified by flash chromatography (0–100% EtOAc in heptane) to afford the titled compounds.

General Method 4. Oxazolines (1 equiv) were dissolved in 3 M HCl (30 equiv) and heated to 100 °C for 18 h and then allowed to cool to rt. The reaction mixtures were neutralized with NaHCO₃ (saturated solution) and extracted with DCM. The organics were separated, dried through a hydrophobic frit, and concentrated *in vacuo* to afford the titled compounds.

General Method 5. Bromides (1 equiv), aldehydes (1.2 equiv), Pd(OAc)₂ (3 mol %), Xantphos (4.5 mol %), and KF (2.5 equiv) were combined in DMF (0.12 M) in sealed tubes. The reaction mixtures were heated to 80 °C for 18 h. The reactions were quenched with H₂O and stirred at rt for 10 min. DCM was added and the mixtures were filtered through Celite and washed with further DCM. The combined organics were concentrated *in vacuo* and purified by preparative HPLC (XBridge column, 0.1% NH₄OH modifier), and the fractions were concentrated *in vacuo* to afford the titled compounds.

General Method 6a. Esters (1 equiv) were dissolved in DCM (0.2–0.4 M) and cooled to –78 °C under N₂. DIBAL (2.5 equiv, 1 M in DCM) was added dropwise over 20 min, and the reactions were stirred for 1 h at –78 °C. The reaction mixtures were quenched carefully with H₂O and MeOH (1:1, 10 mL) and allowed to warm to rt. DCM was added and the mixtures were passed through hydrophobic frits. The organics were concentrated *in vacuo*, and the crude products were purified by flash chromatography (0–100% EtOAc in heptane) to afford the titled compounds.

General Method 6b. Esters (1 equiv) were dissolved in DCM (0.2–0.4 M) and cooled to –78 °C under N₂. DIBAL (2.5 equiv, 1 M in DCM) was added dropwise over 20 min and the reactions were stirred for 1 h at –78 °C. The reaction mixtures were quenched carefully with H₂O and MeOH (1:1, 10 mL) and allowed to warm to rt. DCM was added and the mixtures were passed through hydrophobic frits. The organics were concentrated *in vacuo* to afford the alcohols. The residues were redissolved in DCM and MnO₂ (10 equiv) was added. The reaction mixtures were stirred at rt for 18 h, then filtered through Celite cartridges, and washed well with DCM and MeOH. The solvents were removed *in vacuo* to afford the titled compounds.

Synthesis of 1-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] (1) (Scheme 1). 5-Methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (**70**). Ethyl 5-methyl-1-phenyl-1H-pyrazole-3-carboxylate (2.00 g, 8.69 mmol) and DIBAL (1 M in DCM) (21.72 mL, 21.72 mmol) were combined in DCM (20 mL) according to General Method 6a. Work-up and purification afforded the title compound as a pale yellow oil (678 mg, 41%). LCMS (ESI) *m/z*: 189 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.50–7.42 (m, 4H), 7.42–7.37 (m, 1H), 6.22 (s, 1H), 4.72 (d, *J* = 5.9 Hz, 2H), 2.34 (s, 3H), 2.10 (br s, 1H).

1-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] (1). 5-Meth-

yl-1-phenyl-pyrazole-3-carbaldehyde (**70**) (40 mg, 0.21 mmol), spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine] (43 mg, 0.20 mmol), and sodium triacetoxyborohydride (91 mg, 0.43 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (30 mg, 35%). HRMS (ESI) *m/z*: calcd for C₂₂H₂₆N₃OS [M + H]⁺, 380.1791; found, 380.1794. ¹H NMR (500 MHz, CDCl₃): δ 7.47 (d, *J* = 4.4 Hz, 4H), 7.39–7.35 (m, 1H), 7.15 (d, *J* = 5.0 Hz, 1H), 6.78 (d, *J* = 5.0 Hz, 1H), 6.24 (s, 1H), 3.94 (dd, *J* = 5.5, 5.5 Hz, 2H), 3.67 (s, 2H), 2.88 (d, *J* = 11.6 Hz, 2H), 2.72 (dd, *J* = 5.5, 5.5 Hz, 2H), 2.58–2.51 (m, 2H), 2.36 (s, 3H), 2.07–2.03 (m, 4H).

Synthesis of 1'-((1-Methyl-5-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (2) (Scheme 1). Spiro[isochromane-1,4'-piperidine] (98 mg, 0.48 mmol), 3-(chloromethyl)-1-methyl-5-phenyl-1H-pyrazole (**54**) (50 mg, 0.24 mmol), and diisopropylethylamine (93 mg, 0.73 mmol) were combined in DMSO (1 mL) and stirred at rt for 18 h. Water (0.3 mL) was added, the mixture was purified by preparative HPLC (XBridge column, 0.1% NH₄OH modifier), and the fractions were concentrated *in vacuo* to afford the title compound (40 mg, 42%). HRMS (ESI) *m/z*: calcd for C₂₄H₂₈N₃O [M + H]⁺, 374.2232; found, 374.2180. ¹H NMR (500 MHz, CDCl₃): δ 7.46–7.40 (5H, m), 7.22–7.12 (3H, m), 7.08 (1H, d, *J* = 7.3 Hz), 6.31 (1H, s), 3.91 (2H, t, *J* = 5.5 Hz), 3.88 (3H, s), 3.64 (2H, s), 2.90–2.87 (2H, m), 2.83 (2H, t, *J* = 8.1 Hz), 2.55–2.48 (2H, m), 2.14–2.06 (2H, m), 1.91 (2H, d, *J* = 11.8 Hz).

Synthesis of 1-(4-(4-(Trifluoromethoxy)phenoxy)benzyl)-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] (3) (Scheme 1). 1-(4-Methoxybenzyl)-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] (**48**). 1-[(4-Methoxyphenyl)methyl]piperidin-4-one (1.71 g, 7.80 mmol) and 2-(thiophen-2-yl)ethan-1-ol (1.00 g, 7.80 mmol) were mixed in toluene (70 mL) and methanesulfonic acid (1 mL, 15.60 mmol) was added. The reaction mixture was heated to 130 °C in Dean–Stark apparatus for 18 h. The reaction mixture was allowed to cool to rt and toluene was removed *in vacuo*. The residue was dissolved in MeOH and loaded onto a 20 g SCX cartridge, eluting with MeOH and 3 M NH₃/MeOH. The crude material was purified further by flash chromatography (0–8% MeOH in DCM with NH₃ modifier) to afford the title compound (940 mg, 35%). ¹H NMR (500 MHz, CDCl₃): δ 6.73 (d, *J* = 2.7 Hz, 3H), 6.55 (d, *J* = 1.7 Hz, 1H), 6.35 (dd, *J* = 10.8, 10.8 Hz, 2H), 6.31–6.28 (m, 1H), 4.77 (d, *J* = 2.4 Hz, 1H), 3.43–3.38 (m, 2H), 3.29 (d, *J* = 2.3 Hz, 3H), 2.98 (s, 2H), 2.30 (dd, *J* = 5.0, 5.0 Hz, 2H), 2.19–2.16 (m, 2H), 1.44 (dd, *J* = 12.1, 12.1 Hz, 2H), 1.32 (d, *J* = 12.8 Hz, 2H).

6',7'-Dihydro-1,2-spiro[piperidine-4,4'-thieno[3,2-c]pyran] (49). 1'-[(4-Methoxyphenyl)methyl]spiro[6,7-dihydrothieno[3,2-c]pyran-4,4'-piperidine] (**48**) (940 mg, 2.85 mmol) was dissolved in DCM (15 mL) under N₂ and cooled to 0 °C. 1-Chloroethyl carbonochloridate (530 mg, 3.71 mmol) in DCM (3 mL) was then added dropwise, and the reaction mixture was stirred at 0 °C for 30 min and then allowed to warm up to rt. The volatiles were removed *in vacuo*, and the residue was dissolved in MeOH (15 mL) and heated to reflux for 1 h. After cooling to rt, the reaction mixture was passed through a 20 g SCX cartridge, eluting the amine with 3 M NH₃/MeOH to afford the title compound as a pale orange gum, which solidified on standing at rt (480 mg, 76%). ¹H NMR (400 MHz, CDCl₃): δ 7.10 (d, *J* = 5.2 Hz, 1H), 6.83 (d, *J* = 5.2

H₂, 1H), 3.97 (dd, *J* = 5.4, 5.4 Hz, 2H), 3.11–3.03 (m, 2H), 2.95–2.83 (m, 4H), 1.88–1.83 (m, 4H).

1'-[[4-[4-(Trifluoromethoxy)phenoxy]phenyl]methyl]spiro[6,7-dihydrothieno[3,2-*c*]pyran-4,4'-piperidine] (3). 4-(Trifluoromethoxy)phenol (1.0 g, 5.61 mmol) and 4-fluorobenzaldehyde (697 mg, 5.61 mmol) were mixed in DMF (10 mL) and K₂CO₃ (931 mg, 6.74 mmol) was added. The reaction mixture was heated at 140 °C for 8 h and then allowed to cool to rt. H₂O was added and the product was extracted with Et₂O. The combined organics were washed with brine, dried (MgSO₄), and concentrated *in vacuo* to afford 4-(4-(trifluoromethoxy)phenoxy)benzaldehyde as a yellow oil (1.40 g, 80%). ¹H NMR (500 MHz, CDCl₃): δ 9.98 (s, 1H), 7.90 (d, 2H), 7.30 (m, 2H), 7.11 (m, 4H). 4-[4-(Trifluoromethoxy)phenoxy]benzaldehyde (60 mg, 0.21 mmol), 6',7'-dihydro-1,2-spiro[piperidine-4,4'-thieno[3,2-*c*]pyran] (49) (45 mg, 0.21 mmol), and sodium triacetoxyborohydride (90 mg, 0.43 mmol) were combined in DCM (3 mL) according to General Method 1. Work-up and purification afforded the title compound (52 mg, 51%). LCMS (ESI) *m/z*: 476 [M + H]⁺. HRMS (ESI) *m/z*: calcd for C₂₅H₂₅F₃NO₃S [M + H]⁺, 476.1507; found, 476.1489. ¹H NMR (500 MHz, CDCl₃): δ 7.34 (d, *J* = 8.6 Hz, 2H), 7.19–7.15 (m, 2H), 7.07 (d, *J* = 5.2 Hz, 1H), 7.02–6.96 (m, 4H), 6.81 (d, *J* = 5.2 Hz, 1H), 3.93 (t, *J* = 5.4 Hz, 2H), 3.54 (s, 1H), 2.83 (t, *J* = 5.4 Hz, 2H), 2.75–2.70 (m, 2H), 2.40 (td, *J* = 12.1, 2.6 Hz, 2H), 1.97 (td, *J* = 13.4, 4.4 Hz, 2H), 1.89–1.83 (m, 2H).

Synthesis of 1'-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (4) (Scheme 1). Spiro[isochromane-1,4'-piperidine] (200 mg, 0.98 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (183 mg, 0.98 mmol), and sodium triacetoxyborohydride (417 mg, 1.97 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (244 mg, 65%). LCMS (ESI) *m/z*: 374 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₄H₂₈N₃O [M + H]⁺, 374.2227; found, 374.2235. ¹H NMR (400 MHz, CDCl₃): δ 7.47–7.43 (m, 4H), 7.38–7.32 (m, 1H), 7.23–7.11 (m, 3H), 7.10–7.06 (m, 1H), 6.22 (s, 1H), 3.90 (t, *J* = 5.6 Hz, 2H), 3.66 (s, 1H), 2.89–2.80 (m, 4H), 2.52 (t, *J* = 12.1 Hz, 2H), 2.34 (d, *J* = 0.7 Hz, 3H), 2.08 (td, *J* = 13.2, 4.5 Hz, 2H), 1.95–1.87 (m, 2H).

Synthesis of 9-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-1-oxa-9-azaspiro[5.5]undecane (5) (Scheme 1). 1-Oxa-9-azaspiro[5.5]undecane hydrochloride (50 mg, 0.26 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (51 mg, 0.27 mmol), and sodium triacetoxyborohydride (110 mg, 0.52 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) *m/z*: 326 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.45–7.42 (m, 3H), 7.36–7.32 (m, 1H), 6.17 (s, 1H), 3.63 (t, *J* = 5.2 Hz, 2H), 3.58 (s, 2H), 2.63 (m, 2H), 2.44 (m, 2H), 2.32 (d, *J* = 0.5 Hz, 3H), 1.89 (d, *J* = 13.4, 2H), 1.63–1.48 (m, 6H), 1.47–1.41 (m, 2H).

Synthesis of 6-Fluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (6) (Scheme 1). *tert*-Butyl 4-(4-fluoro-2-(2-hydroxyethyl)phenyl)-4-hydroxypiperidine-1-carboxylate (40). 2-(2-Bromo-5-fluorophenyl)ethan-1-ol (6.48 g, 29.58 mmol) was dissolved in THF (10 mL) and cooled to –78 °C. 2.5 M *n*-BuLi solution (23.67 mL, 59.17 mmol) was added dropwise and continuously stirred at –78 °C for 1 h. *tert*-Butyl 4-oxopiperidine-1-carboxylate (5.89 g, 29.58 mmol) was dissolved in THF (10

mL), and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at –78 °C for 1 h before allowing to warm slowly to rt over 18 h. The reaction was quenched with NH₄Cl (saturated solution), EtOAc was added, and the organic layer was separated and dried (hydrophobic frit). The crude material was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) *m/z*: 240 (M-CO₂tBu + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.24 (dd, *J* = 8.9, 5.9 Hz, 1H), 6.89 (dd, *J* = 10.0, 2.8 Hz, 1H), 6.84 (ddd, *J* = 8.9, 7.8, 2.8 Hz, 1H), 3.94 (br s, 2H), 3.89–3.84 (m, 2H), 3.31–3.19 (br m, 4H), 1.94–1.86 (m, 2H), 1.82 (d, *J* = 12.7 Hz, 2H), 1.80–1.75 (m, 2H), 1.44 (s, 9H).

***tert*-Butyl 6-Fluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (44).** *tert*-Butyl 4-[4-fluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxypiperidine-1-carboxylate (40) (3.48 g, 10.25 mmol) and triethylamine (2.86 mL, 20.51 mmol) were combined in DCM (15 mL) and cooled to 0 °C. Methanesulfonyl chloride (0.79 mL, 10.25 mmol) was added dropwise and the reaction was allowed to warm to rt and then heated to reflux for 90 min. The reaction was then allowed to cool to rt and washed with H₂O. The organics were separated and concentrated *in vacuo*. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound (1.96 g, 59%). ¹H NMR (400 MHz, CDCl₃): δ 7.03 (dd, *J* = 8.7, 5.5 Hz, 1H), 6.88 (td, *J* = 8.5, 2.7 Hz, 1H), 6.79 (dd, *J* = 9.3, 2.7 Hz, 1H), 3.99 (br s, 2H), 3.89 (t, *J* = 5.5 Hz, 2H), 3.13 (br s, 2H), 2.81 (t, *J* = 5.5 Hz, 2H), 1.90–1.76 (m, 4H), 1.49 (s, 9H).

6-Fluorospiro[isochromane-1,4'-piperidine] (50). *tert*-Butyl 6-fluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (44) (1.96 g, 6.10 mmol) was dissolved in DCM (5 mL) and trifluoroacetic acid (4.17 mL, 54.50 mmol) was added. The reaction was stirred at rt for 18 h. The reaction mixture was diluted with MeOH and loaded onto an SCX cartridge eluting with MeOH and then 3 M NH₃ in MeOH to elute the product. The solvents were removed *in vacuo* to afford the title compound (1.21 g, 90%). LCMS (ESI) *m/z*: 222 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.13 (dd, *J* = 8.7, 5.7 Hz, 1H), 6.88 (td, *J* = 8.7, 2.7 Hz, 1H), 6.78 (dd, *J* = 9.3, 2.7 Hz, 1H), 3.89 (t, *J* = 5.5 Hz, 2H), 3.11–3.02 (m, 2H), 2.93–2.86 (m, 2H), 2.81 (t, *J* = 5.5 Hz, 2H), 1.89–1.81 (m, 4H).

6-Fluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (6). 6-Fluorospiro[isochromane-1,4'-piperidine] (50) (40 mg, 0.18 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (34 mg, 0.18 mmol), and sodium triacetoxyborohydride (77 mg, 0.36 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) *m/z*: 392 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₄H₂₇FN₃O [M + H]⁺, 392.2138; found, 392.2080. ¹H NMR (500 MHz, CDCl₃): δ 7.46–7.43 (m, 4H), 7.38–7.32 (m, 1H), 7.15 (dd, *J*₁ = 8.7 Hz, *J*₂ = 5.6 Hz, 1H), 6.87 (td, *J*₁ = 8.6 Hz, *J*₂ = 2.7 Hz, 1H), 6.77 (dd, *J*₁ = 9.3 Hz, *J*₂ = 2.7 Hz, 1H), 6.21 (s, 1H), 3.87 (t, *J* = 5.5 Hz, 2H), 3.65 (s, 2H), 2.85 (m, 2H), 2.80 (t, *J* = 5.5 Hz, 2H), 2.51 (t, *J* = 13.1 Hz, 2H), 2.33 (d, *J* = 0.6 Hz, 3H), 2.10–2.00 (m, 2H), 1.91–1.84 (m, 2H).

Synthesis of 7-Fluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (7) (Scheme 1). 7-Fluorospiro[isochromane-1,4'-piperidine] (40 mg, 0.18 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (34 mg, 0.18 mmol), and sodium triacetoxyborohydride (77

mg, 0.36 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) m/z : 392 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.48–7.42 (m, 4H), 7.38–7.32 (m, 1H), 7.05–7.00 (m, 1H), 6.91 (dd, $J_1 = 10.3$ Hz, $J_2 = 2.6$ Hz, 1H), 6.83 (td, $J_1 = 8.4$ Hz, $J_2 = 2.6$ Hz, 1H), 6.22 (s, 1H), 3.87 (t, $J = 5.5$ Hz, 2H), 3.64 (s, 2H), 2.85 (m, 2H), 2.77 (t, $J = 5.5$ Hz, 2H), 2.55–2.46 (m, 2H), 2.43 (d, $J = 0.6$ Hz, 3H), 2.07–1.97 (m, 2H), 1.93–1.86 (m, 2H).

Synthesis of 6,7-Difluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (8) (Scheme 1). 2-(2-Bromo-4,5-difluoro-phenyl)ethanol (38). 2-(2-Bromo-4,5-difluoro-phenyl)acetic acid (36) (1.04 g, 4.14 mmol) was dissolved in THF (20 mL) and BH₃.THF (1 M solution, 10.8 mL, 10.8 mmol) was added dropwise. The resultant solution was heated to 100 °C for 1 h. The solution was then allowed to cool to rt and H₂O (15 mL) was carefully added until effervescence is ceased, followed by K₂CO₃ portionwise until effervescence is ceased. Et₂O (20 mL) was then added and the layers were separated. The organic liquors were washed with NaHCO₃ (saturated aqueous solution) and brine, dried (MgSO₄), separated *via* a hydrophobic frit and then concentrated *in vacuo* to afford the crude product. Purification by flash chromatography (10–20% EtOAc in heptane) afforded the title compound. ¹H NMR (400 MHz, CDCl₃): δ 7.38 (dd, $J_1 = 11.9$ Hz, $J_2 = 9.7$ Hz, 1H), 7.14 (dd, $J_1 = 10.9$ Hz, $J_2 = 8.2$ Hz, 1H), 3.89–3.82 (m, 2H), 2.95 (t, $J = 6.5$ Hz, 2H), 1.62 (t, $J = 5.4$ Hz, 1H).

tert-Butyl 4-[4,5-Difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (41). 2-(2-Bromo-4,5-difluoro-phenyl)ethanol (38) (954 mg, 4.02 mmol) was dissolved in THF (15 mL) and cooled to –78 °C. *n*-BuLi (2.5 M solution, 3.22 mL, 8.05 mmol) was added dropwise and the mixture was stirred at –78 °C for 1 h. *tert*-Butyl 4-oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) was dissolved in THF (10 mL), and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at –78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL), EtOAc (20 mL) was added, and then the organic layer was separated *via* a hydrophobic frit, dried (MgSO₄), and concentrated *in vacuo* to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) m/z : 358 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.11 (dd, $J_1 = 12.6$ Hz, $J_2 = 8.5$ Hz, 1H), 7.01 (dd, $J_1 = 11.2$ Hz, $J_2 = 8.4$ Hz, 1H), 4.16–3.89 (m, 4H), 3.48 (d, $J = 5.2$ Hz, 2H), 3.34–3.18 (m, 4H), 1.94–1.77 (m, 4H), 1.47 (s, 9H).

tert-Butyl 6,7-Difluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (45). *tert*-Butyl 4-[4,5-difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (41) (185 mg, 0.52 mmol) was dissolved in DCM (6 mL) and Et₃N (154 μL, 1.11 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (43 μL, 0.55 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to rt and washed with H₂O. The volatiles were removed *in vacuo* to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. ¹H NMR (500 MHz, CDCl₃): δ

6.92–6.82 (m, 2H), 4.17–3.80 (m, 4H), 3.28–2.94 (m, 2H), 2.82–2.68 (m, 2H), 1.93–1.70 (m, 4H), 1.49 (s, 9H).

6,7-Difluorospiro[isochromane-1,4'-piperidine] (51). *tert*-Butyl 6,7-difluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (45) (106 mg, 0.31 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (24 μL, 0.31 mmol) at rt for 18 h and then concentrated *in vacuo*. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH₃ in MeOH. The solvents were removed *in vacuo* to afford the title compound. LCMS (ESI) m/z : 240 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 6.96 (dd, $J_1 = 11.6$ Hz, $J_2 = 7.9$ Hz, 1H), 6.86 (dd, $J_1 = 10.7$ Hz, $J_2 = 8.0$ Hz, 1H), 3.86 (t, $J = 5.5$ Hz, 2H), 3.10–3.00 (m, 2H), 2.96–2.87 (m, 2H), 2.80–2.60 (m, 3H), 1.91–1.75 (m, 4H).

6,7-Difluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (8). 6,7-Difluorospiro[isochromane-1,4'-piperidine] (51) (27 mg, 0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (21 mg, 0.11 mmol), and sodium triacetoxyborohydride (48 mg, 0.23 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) m/z : 410 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.50–7.45 (m, 4H), 7.41–7.35 (m, 1H), 7.06–6.97 (m, 1H), 6.99–6.84 (m, 1H), 6.23 (s, 1H), 3.89 (t, $J = 5.6$ Hz, 2H), 3.66 (s, 2H), 2.87 (m, 2H), 2.77 (t, $J = 5.4$ Hz, 2H), 2.51 (td, $J_1 = 11.9$ Hz, $J_2 = 2.8$ Hz, 2H), 2.36 (d, $J = 0.5$ Hz, 3H), 2.06–1.95 (m, 2H), 1.94–1.86 (m, 2H).

Synthesis of 1'-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-6-(Trifluoromethyl)spiro[isochromane-1,4'-piperidine] (9) (Scheme 1). 2-[2-Bromo-5-(trifluoromethyl)phenyl]ethanol (39). 2-[2-Bromo-5-(trifluoromethyl)phenyl]acetic acid (37) (850 mg, 3.00 mmol) was dissolved in THF (10 mL) and BH₃.THF (1 M solution, 3.90 mL, 3.90 mmol) was added dropwise. The resultant solution was heated to 100 °C for 1 h. The solution was then allowed to cool to rt and H₂O (15 mL) was carefully added until effervescence is ceased, followed by K₂CO₃ portionwise until effervescence is ceased. Et₂O (20 mL) was then added and the layers were separated. The organics were washed with NaHCO₃ (saturated aqueous solution) and brine, dried (MgSO₄), separated *via* a hydrophobic frit, and then concentrated *in vacuo* to afford the crude product. This product was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound. ¹H NMR (500 MHz, CDCl₃): δ 7.70–7.66 (m, 1H), 7.56–7.52 (m, 1H), 7.37–7.32 (m, 1H), 3.91 (t, $J = 6.6$ Hz, 2H), 3.08 (t, $J = 6.6$ Hz, 2H).

tert-Butyl 4-Hydroxy-4-[2-(2-hydroxyethyl)-4-(trifluoromethyl)phenyl]piperidine-1-carboxylate (42). 2-[2-Bromo-5-(trifluoromethyl)phenyl]ethanol (39) (780 mg, 2.90 mmol) was dissolved in THF (15 mL) and cooled to –78 °C. *n*-BuLi (2.5 M solution, 2.32 mL, 5.80 mmol) was added dropwise and the mixture was stirred at –78 °C for 1 h. *tert*-Butyl 4-oxopiperidine-1-carboxylate (578 mg, 2.90 mmol) dissolved in THF (10 mL) and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at –78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL). EtOAc (20 mL) was added and the organic layer was separated *via* a hydrophobic frit, dried (MgSO₄), and concentrated *in vacuo* to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. ¹H NMR (400 MHz, CDCl₃): δ 7.46–7.38 (m,

3H), 4.31 (br s, 1H), 4.10–3.88 (m, 3H), 3.52–3.19 (m, 6H), 2.03–1.77 (m, 4H), 1.47 (s, 9H).

tert-Butyl 6-(Trifluoromethyl)spiro[isochromane-1,4'-piperidine]-1'-carboxylate (46). *tert*-Butyl 4-hydroxy-4-[2-(2-hydroxyethyl)-4-(trifluoromethyl)phenyl]piperidine-1-carboxylate (42) (342 mg, 0.88 mmol) was dissolved in DCM (6 mL) and Et₃N (245 μ L, 1.76 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (68 μ L, 0.88 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to rt and washed with H₂O. The organics were concentrated *in vacuo* to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) *m/z*: 372 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.43 (d, *J* = 8.2 Hz, 1H), 7.36 (s, 1H), 7.19 (d, *J* = 8.2 Hz, 1H), 4.17–3.87 (m, 4H), 3.15 (br s, 2H), 2.93–2.83 (m, 2H), 1.93–1.78 (m, 4H), 1.49 (s, 9H).

6-(Trifluoromethyl)spiro[isochromane-1,4'-piperidine] (52). *tert*-Butyl 6-(trifluoromethyl)spiro[isochromane-1,4'-piperidine]-1'-carboxylate (46) (169 mg, 0.46 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (0.5 mL, 6.53 mmol) at rt for 18 h and then concentrated *in vacuo*. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH₃ in MeOH. The solvents were removed *in vacuo* to afford the title compound. LCMS (ESI) *m/z*: 272 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.45–7.24 (m, 3H), 3.91–3.85 (m, 2H), 3.79 (br s, 1H), 3.12–3.02 (m, 2H), 2.99–2.90 (m, 2H), 2.89–2.79 (m, 2H), 2.00–1.78 (m, 4H).

1'-((5-Methyl-1-phenyl-1H-pyrazol-3-yl)methyl)-6-(trifluoromethyl)spiro[isochromane-1,4'-piperidine] (9). 6-(Trifluoromethyl)spiro[isochromane-1,4'-piperidine] (52) (31 mg, 0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (70) (21 mg, 0.11 mmol), and sodium triacetoxyborohydride (48 mg, 0.23 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) *m/z*: 442 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.50–7.42 (m, 5H), 7.40–7.32 (m, 3H), 6.24 (s, 1H), 3.93 (t, *J* = 5.5 Hz, 2H), 3.68 (s, 2H), 2.94–2.85 (m, 2H), 2.60–2.49 (m, 2H), 2.36 (d, *J* = 0.7 Hz, 3H), 2.16–2.04 (m, 2H), 1.96–1.88 (m, 2H).

Synthesis of 7,8-Difluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (10) (Scheme 1). *tert*-Butyl 4-[4,5-difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (43). 2-(2-Bromo-4,5-difluoro-phenyl)ethanol (954 mg, 4.02 mmol) was dissolved in THF (15 mL) and cooled to –78 °C. *n*-BuLi (2.5 M solution, 3.22 mL, 8.05 mmol) was added dropwise and the mixture was stirred at –78 °C for 1 h. *tert*-Butyl 4-oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) dissolved in THF (10 mL) and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at –78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL). EtOAc (20 mL) was added and the organic layer was separated *via* a hydrophobic frit, dried (MgSO₄), and concentrated *in vacuo* to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) *m/z*: 358 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.02–6.93 (m, 1H), 6.87–6.80 (m, 1H),

4.00–3.75 (m, 4H), 3.61–3.04 (m, 6H), 2.47–2.31 (m, 2H), 1.68–1.56 (m, 2H), 1.46 (s, 9H).

tert-Butyl 7,8-Difluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (47). *tert*-Butyl 4-[4,5-difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (43) (198 mg, 0.55 mmol) was dissolved in DCM (6 mL) and Et₃N (155 μ L, 1.11 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (43 μ L, 0.55 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to room temperature (rt) and washed with water. The organic liquors were concentrated *in vacuo* to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. ¹H NMR (500 MHz, CDCl₃): δ 7.02–6.95 (m, 1H), 6.88–6.82 (m, 1H), 4.15–3.83 (m, 4H), 3.31–3.01 (m, 2H), 2.84–2.72 (m, 2H), 2.32–2.22 (m, 2H), 1.89–1.67 (m, 2H), 1.49 (s, 9H).

7,8-Difluorospiro[isochromane-1,4'-piperidine] (53). *tert*-Butyl 7,8-difluorospiro[isochromane-1,4'-piperidine]-1'-carboxylate (47) (81 mg, 0.24 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (18 μ L, 0.24 mmol) at rt for 18 h and then concentrated *in vacuo*. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH₃ in MeOH. The solvents were removed *in vacuo* to afford the title compound. LCMS (ESI) *m/z*: 240 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.01–6.92 (m, 1H), 6.86–6.79 (m, 1H), 3.86 (t, *J* = 5.5 Hz, 2H), 3.40 (br s, 1H), 3.17–3.05 (m, 2H), 3.01–2.90 (m, 2H), 2.80–2.71 (m, 2H), 2.35–2.22 (m, 2H), 1.85–1.76 (m, 2H).

7,8-Difluoro-1'-((5-methyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (10). 7,8-Difluorospiro[isochromane-1,4'-piperidine] (53) (26 mg, 0.11 mmol), 5-methyl-1-phenyl-1H-pyrazole-3-carbaldehyde (20 mg, 0.11 mmol), and sodium triacetoxyborohydride (46 mg, 0.22 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) *m/z*: 410 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.48–7.42 (m, 4H), 7.38–7.31 (m, 1H), 7.02–6.92 (m, 1H), 6.85–6.79 (m, 1H), 6.24 (s, 1H), 3.85 (t, *J* = 5.5 Hz, 2H), 3.65 (s, 2H), 2.86–2.73 (m, 4H), 2.59–2.41 (m, 4H), 2.34 (d, *J* = 0.7 Hz, 3H), 1.85–1.77 (m, 2H).

Synthesis of 1'-((5-Methoxy-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (11) (Scheme 1). **Methyl 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (62).** Phenylhydrazine (5.00 g, 46.24 mmol) in Et₂O (100 mL) was added over 30 min to a mixture of dimethyl but-2-ynedioate (61) (6.57 g, 46.24 mmol) in Et₂O (50 mL). After stirring for 1 h at rt, the reaction mixture was concentrated *in vacuo* and redissolved in MeOH (150 mL). This solution was added dropwise over 1 h to NaOMe (25 wt %) (3.99 mg, 184.94 mmol) in MeOH (150 mL) and the mixture was stirred at rt for 18 h. The solvent was removed *in vacuo* and 5 N HCl (100 mL) was added. The resulting precipitate was collected by filtration, washed with DCM and Et₂O, and air-dried to afford 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylic acid (8.00 g, 76%). ¹H NMR (400 MHz, DMSO): δ 7.74 (d, *J* = 7.5 Hz, 2H), 7.51 (dd, *J* = 7.9, 7.9 Hz, 2H), 7.36 (dd, *J* = 7.4, 7.4 Hz, 1H), 5.93 (s, 1H). 5-Oxo-1-phenyl-4H-pyrazole-3-carboxylic acid (8.00 g, 39.18 mmol) was mixed in MeOH (150 mL), and a few drops of concentrated H₂SO₄ were added. The reaction was heated to reflux for 48 h and then allowed to cool to rt. The volatiles were

removed *in vacuo* and the crude material was purified by flash chromatography (50–100% EtOAc in heptane) to afford the title compound as a pale brown solid (4.00 g, 42%). ¹H NMR (400 MHz, DMSO): δ 12.15 (m, 1H), 7.74 (d, J = 7.6 Hz, 2H), 7.51 (dd, J = 7.9, 7.9 Hz, 2H), 7.38 (dd, J = 7.4, 7.4 Hz, 1H), 5.97 (s, 1H), 3.81 (s, 3H).

Methyl 5-Methoxy-1-phenyl-1H-pyrazole-3-carboxylate (63). Methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (62) (500 mg, 2.29 mmol) was dissolved in THF (10 mL), and PPh₃ (901 mg, 3.44 mmol) and MeOH (0.12 mL, 2.98 mmol) were added. The reaction mixture was cooled to 0 °C and DIAD (0.68 mL, 3.44 mmol) was added dropwise. The reaction mixture was allowed to warm to rt for 18 h. The reaction mixture was partitioned between H₂O and DCM, passed through a hydrophobic frit, and concentrated *in vacuo*. The crude material was purified by flash chromatography (0–100% EtOAc in heptane) to afford the title compound as a yellow gum. DIAD side product coeluted but used in the next step with no further purification. ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J = 8.1 Hz, 2H), 7.46 (dd, J = 7.8, 7.8 Hz, 2H), 7.36 (dd, J = 7.4, 7.4 Hz, 1H), 6.26 (s, 1H), 4.00 (s, 3H), 3.96 (s, 3H).

5-Methoxy-1-phenyl-1H-pyrazole-3-carbaldehyde (71). Methyl 5-methoxy-1-phenyl-pyrazole-3-carboxylate (63) (600 mg, 2.58 mmol) was mixed with THF (8 mL) and cooled to 0 °C. LiAlH₄ (2.58 mL, 2.58 mmol) was added dropwise over 10 min. After 1 h, the reaction was quenched with H₂O (2 mL) and 2 M NaOH (2 mL). The resulting slurry was filtered through a Celite cartridge and concentrated *in vacuo*. The crude material was purified by flash chromatography (0–100% EtOAc in heptane) to afford (5-methoxy-1-phenyl-1H-pyrazol-3-yl)methanol as a pale yellow gum (180 mg, 32%). ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J = 7.6 Hz, 2H), 7.44 (dd, J = 7.9, 7.9 Hz, 2H), 7.29 (m, 1H), 5.74 (s, 1H), 4.69 (d, J = 5.3 Hz, 2H), 3.97 (s, 3H), 2.60 (s, 1H). (5-Methoxy-1-phenyl-pyrazol-3-yl)methanol (300 mg, 1.47 mmol) was dissolved in DCM (10 mL) and MnO₂ (319 mg, 3.67 mmol) was added. The reaction mixture was heated to reflux for 48 h and then allowed to cool to rt. The reaction mixture was filtered through a Celite cartridge and washed with DCM. The filtrate was concentrated *in vacuo* and purified by flash chromatography (0–100% EtOAc in heptane) to afford the title compound (220 mg, 70%). ¹H NMR (400 MHz, CDCl₃): δ 9.92 (s, 1H), 7.76 (d, J = 7.8 Hz, 2H), 7.51 (dd, J = 7.8, 7.8 Hz, 2H), 7.41 (dd, J = 7.4, 7.4 Hz, 1H), 6.22 (s, 1H), 4.02 (s, 3H).

1'-((5-Methoxy-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (11). Spiro[isochromane-1,4'-piperidine] (40 mg, 0.20 mmol), 5-methoxy-1-phenyl-1H-pyrazole-3-carbaldehyde (71) (40 mg, 0.20 mmol), and sodium triacetoxyborohydride (83 mg, 0.39 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded 1'-((5-methoxy-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] as a colorless gum (40 mg, 50%). HRMS (ESI) m/z : calcd for C₂₄H₂₈N₃O₂ [M + H]⁺, 390.2181; found, 390.2165. ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, J = 7.6 Hz, 1H), 7.43 (dd, J = 8.0, 8.0 Hz, 1H), 7.27–7.09 (m, 2H), 3.97 (s, 2H), 3.92 (dd, J = 5.5, 5.5 Hz, 1H), 3.63 (s, 1H), 2.89–2.83 (m, 2H), 2.60–2.52 (m, 1H), 2.16–2.03 (m, 1H), 1.94 (d, J = 12.3 Hz, 1H).

Synthesis of 1'-((5-Cyclopropyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (12) (Scheme 1). Methyl 5-Cyclopropyl-1-phenyl-1H-pyrazole-3-carboxylate (64). Phenylhydrazine (634 mg, 5.88 mmol) was added to

a solution of methyl 4-cyclopropyl-2,4-dioxo-butanoate (55) (1.00 g, 5.88 mmol) in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded the title compound (1.16 g, 81%). LCMS (ESI) m/z : 243 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.63–7.59 (m, 2H), 7.51–7.48 (m, 2H), 7.44–7.40 (m, 1H), 6.50 (s, 1H), 3.92 (s, 3H), 1.81–1.74 (m, 1H), 1.03–0.97 (m, 2H), 0.82–0.76 (m, 2H).

5-Cyclopropyl-1-phenyl-1H-pyrazole-3-carbaldehyde (72). Methyl 5-cyclopropyl-1-phenyl-1H-pyrazole-3-carboxylate (64) (1.16 g, 4.79 mmol) and DIBAL (1 M in DCM) (11.97 mL, 11.97 mmol) were combined in DCM (25 mL) according to General Method 6a. Work-up and purification afforded the title compound (719 mg, 67%). LCMS (ESI) m/z : 213 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 9.97 (s, 1H), 7.66–7.62 (m, 2H), 7.55–7.50 (m, 2H), 7.48–7.44 (m, 1H), 6.48 (s, 1H).

1'-((5-Cyclopropyl-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (12). Spiro[isochromane-1,4'-piperidine] (48 mg, 0.24 mmol), 5-cyclopropyl-1-phenyl-1H-pyrazole-3-carbaldehyde (72) (50 mg, 0.24 mmol), and sodium triacetoxyborohydride (100 mg, 0.47 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (20 mg, 20%). LCMS (ESI) m/z : 400 (M + H)⁺. HRMS (ESI) m/z : calcd for C₂₆H₃₀N₃O [M + H]⁺, 400.2383; found, 400.2389. ¹H NMR (500 MHz, CDCl₃): δ 7.65–7.61 (m, 2H), 7.48–7.43 (m, 2H), 7.34 (tdd, J = 7.5, 1.5, 1.2 Hz, 1H), 7.21 (dd, J = 7.8, 1.6 Hz, 1H), 7.18 (td, J = 7.3, 1.6 Hz, 1H), 7.13 (td, J = 7.3, 1.6 Hz, 1H), 7.08 (d, 7.3 Hz, 1H), 5.99 (s, 1H), 3.89 (t, J = 5.6 Hz, 2H), 3.63 (s, 2H), 2.87–2.80 (m, 4H), 2.50 (td, J = 11.9, 2.3 Hz, 2H), 2.08 (td, J = 13.2, 4.6 Hz, 2H), 1.93–1.87 (m, 2H), 1.84–1.77 (m, 1H), 1.00–0.95 (m, 2H), 0.82–0.77 (m, 2H).

Synthesis of 1'-((5-(Difluoromethyl)-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (13) (Scheme 1). Ethyl 5-(Difluoromethyl)-1-phenyl-1H-pyrazole-3-carboxylate (65). Ethyl 5,5-difluoro-2,4-dioxo-pentanoate (56) (1.00 g, 5.15 mmol) and phenylhydrazine (557 mg, 5.15 mmol) were dissolved in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded an intermediate compound. This material was then dissolved in THF, 2 M HCl was added, and the mixture was heated to reflux for 18 h. The volatiles were removed *in vacuo* and the product was extracted with DCM, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound as a colorless oil (850 mg, 62%). LCMS (ESI) m/z : 267 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.55 (s, 6H), 6.63 (t, J = 53.4 Hz, 1H), 4.47 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.2 Hz, 3H).

5-(Difluoromethyl)-1-phenyl-1H-pyrazole-3-carbaldehyde (73). Ethyl 5-(difluoromethyl)-1-phenyl-1H-pyrazole-3-carboxylate (65) (187 mg, 0.70 mmol) and DIBAL (1 M in DCM) (1.76 mL, 1.76 mmol) were combined in DCM (10 mL) with MnO₂ (1.22 g, 14.05 mmol) added in the second step according to General Method 6b. Work-up and purification afforded the title compound as a colorless oil (122 mg, 74%).

1'-((5-(Difluoromethyl)-1-phenyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (13). Spiro[isochromane-1,4'-piperidine] (62 mg, 0.30 mmol), 5-(difluoromethyl)-1-phenyl-1H-pyrazole-3-carbaldehyde (73) (61 mg, 0.27 mmol), and sodium triacetoxyborohydride (116 mg, 0.55 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (10 mg, 8%). LCMS (ESI) m/z : 428 (M + H)⁺.

HRMS (ESI) m/z : calcd for $C_{24}H_{26}F_2N_3O$ [$M + H^+$], 410.2053; found, 410.2054. 1H NMR (500 MHz, $CDCl_3$): δ 7.56–7.44 (m, 5H), 7.26–7.19 (m, 2H), 7.17 (td, $J = 7.0, 2.0$ Hz, 1H), 7.11 (d, $J = 7.5$ Hz, 1H), 6.80 (s, 1H), 6.65 (t, $J = 5.4$ Hz, 3.93 (t, $J = 5.5, 2H$), 3.74 (s, 2H), 2.89–2.83 (m, 4H), 2.56 (t, $J = 12.2$ Hz, 2H), 2.11 (td, $J = 13.2, 4.2$ Hz, 2H), 1.94 (d, $J = 13.2$ Hz, 2H).

Synthesis of 1'-((1-Phenyl-5-(Trifluoromethyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (14) (Scheme 1). Ethyl 1-Phenyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (66). Phenylhydrazine (510 mg, 4.71 mmol) and ethyl 5,5,5-trifluoro-2,4-dioxo-pentanoate (57) (1.00 g, 4.71 mmol) were dissolved in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded an intermediate compound. This material was then dissolved in THF, 2 M HCl was added, and the mixture was heated to reflux for 18 h. The volatiles were removed *in vacuo*, and the product was extracted with DCM, dried *via* a hydrophobic frit, and concentrated *in vacuo*. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound as a yellow oil (456 mg, 34%). LCMS (ESI) m/z : 285 ($M + H^+$). 1H NMR (400 MHz, $CDCl_3$): δ 7.54–7.47 (m, 5H), 7.33 (s, 1H), 4.45 (q, $J = 7.2, 2H$), 1.41 (t, $J = 7.2, 3H$).

1-Phenyl-5-(Trifluoromethyl)-1H-pyrazole-3-carbaldehyde (74). Ethyl 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (66) (417 mg, 1.47 mmol) and DIBAL (1 M in DCM) (3.67 mL, 3.67 mmol) were combined in DCM (10 mL) with MnO_2 (273 mg, 3.14 mmol) added in the second step according to General Method 6b. Work-up afforded the crude product which was used without further purification.

1'-((1-Phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (14). Spiro[isochromane-1,4'-piperidine] (49 mg, 0.24 mmol), 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-3-carbaldehyde (74) (52 mg, 0.22 mmol), and sodium triacetoxyborohydride (92 mg, 0.43 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (20 mg, 21%). LCMS (ESI) m/z : 428 ($M + H^+$). 1H NMR (500 MHz, $CDCl_3$): δ 7.51–7.43 (m, 5H), 7.23–7.17 (m, 1H), 7.09 (d, $J = 7.6$ Hz, 1H), 6.84 (s, 1H), 3.90 (t, $J = 5.5$ Hz, 2H), 3.70 (s, 2H), 2.85–2.80 (m, 4H), 2.53 (td, 12.0, 2.5 Hz, 2H), 2.08 (td, 13.3, 4.4 Hz, 2H), 1.95–1.89 (m, 2H).

Synthesis of (4-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)phenyl)methanol (15) (Scheme 1). 1'-((5-Methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (78). To 5-methyl-1H-pyrazole-3-carbaldehyde (1.35 g, 12.30 mmol) in NMP (125 mL) were added spiro[isochromane-1,4'-piperidine] (2.50 g, 12.30 mmol) and a few drops of acetic acid. After 1 h at rt, sodium triacetoxyborohydride (5.21 mg, 24.60 mmol) was added. The reaction mixture was stirred at rt for 18 h. The reaction was quenched with $NaHCO_3$ (saturated aqueous solution), and the product was extracted with EtOAc, washed with brine, dried (Na_2SO_4), and concentrated *in vacuo*. The residue was loaded onto a 20 g SCX cartridge eluting with MeOH and then 20% 2 N NH_3 /MeOH. The volatiles were removed *in vacuo* to afford the title compound as a pale yellow solid (320 mg, 8%). The initial MeOH washings were concentrated *in vacuo*, and the resulting material was purified by flash chromatography (0–5% MeOH in DCM) to afford a second batch of title compound as a pale yellow solid (1.60 g, 42%). 1H NMR (400 MHz, $CDCl_3$): δ 7.22–7.21 (m, 2H), 7.18–7.14 (m, 1H), 7.10 (d, $J = 7.34$

Hz), 6.02 (s, 1H), 3.91 (t, $J = 5.5$ Hz, 2H), 3.61 (s, 2H), 2.84 (t, $J = 5.5$ Hz, 2H), 2.78–2.75 (m, 2H), 2.49 (t, $J = 11.5$ Hz, 2H), 2.31 (s, 3H), 2.06 (td, $J = 13.5, 3.8$ Hz, 2H), 1.93–1.90 (m, 2H). LCMS (ESI) m/z : 298 ($M + H^+$).

(4-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)phenyl)methanol (15). 1'-[(5-methyl-1H-pyrazol-3-yl)methyl]spiro[isochromane-1,4'-piperidine] (78) (100 mg, 0.34 mmol), [4-(hydroxymethyl)phenyl]boronic acid (102 mg, 0.67 mmol), and copper acetate (92 mg, 0.50 mmol) were combined in DCM (3 mL) and pyridine (0.50 mL, 6.20 mmol) according to General Method 2. Work-up and purification afforded the title compound (30 mg, 21%). HRMS (ESI) m/z : calcd for $C_{25}H_{30}N_3O_2$ [$M + H^+$], 404.2338; found, 404.2365. 1H NMR (400 MHz, $CDCl_3$): δ 7.43 (s, 4H), 7.25–7.09 (m, 4H), 6.24 (s, 1H), 4.76 (s, 2H), 3.92 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.68 (s, 2H), 2.89–2.82 (m, 4H), 2.59–2.51 (m, 3H), 2.34 (s, 3H), 2.16–2.06 (m, 2H), 1.92 (d, $J = 12.2$ Hz, 2H).

Synthesis of 1'-((5-Methyl-1-(p-tolyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (16) (Scheme 1). 1'-[(5-methyl-1H-pyrazol-3-yl)methyl]spiro[isochromane-1,4'-piperidine] (78) (50 mg, 0.17 mmol), *p*-tolylboronic acid (46 mg, 0.34 mmol), and copper acetate (46 mg, 0.25 mmol) were combined in DCM (1 mL) and pyridine (0.27 mL) according to General Method 2. Work-up and purification afforded the title compound as a yellow gum (15 mg, 22%). LCMS (ESI) m/z : 388 ($M + H^+$). 1H NMR (400 MHz, $CDCl_3$): δ 7.36–7.32 (m, 2H), 7.28–7.22 (m, 3H), 7.20 (td, $J = 6.83, 1.57$ Hz, 1H), 7.15 (td, $J = 7.32, 1.8$ Hz, 1H), 7.11–7.08 (m, 1H), 6.22 (d, $J = 0.5$ Hz, 1H), 3.9 (t, $J = 5.5$ Hz, 2H), 6.37 (s, 2H), 2.90–2.83 (m, 4H), 2.53 (td, $J = 12.90, 2.44$ Hz, 2H), 2.41 (s, 3H), 2.33 (d, $J = 0.7$ Hz, 3H), 2.10 (td, $J = 13.40, 4.47$ Hz, 2H), 1.95–1.89 (m, 2H).

Synthesis of 1'-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (17) (Scheme 1). Ethyl 5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-3-carboxylate (67). [4-(Trifluoromethoxy)phenyl]hydrazine hydrochloride (4.34 g, 18.97 mmol) and ethyl 2,4-dioxopentanoate (58) (3.00 g, 18.97 mmol) were dissolved in AcOH (25 mL) according to General Method 3b. Work-up and purification afforded the title compound (3.00 g, 48%). 1H NMR (400 MHz, $CDCl_3$): δ 7.55–7.52 (m, 2H), 7.35 (d, $J = 8.3$ Hz, 2H), 6.77 (s, 1H), 4.44 (q, $J = 7.1$ Hz, 2H), 2.37 (s, 3H).

5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-3-carbaldehyde (75). Ethyl 5-methyl-1-[4-(trifluoromethoxy)phenyl]pyrazole-3-carboxylate (67) (2.60 g, 8.27 mmol) and DIBAL (1 M in DCM) (20.68 mL, 20.68 mmol) were combined in DCM (25 mL) according to General Method 6a. Work-up and purification afforded the title compound as a pale yellow oil (2.00 g, 85%). 1H NMR (400 MHz, $CDCl_3$): δ 10.01 (s, 1H), 7.58–7.55 (m, 2H), 7.41 (d, $J = 8.3$ Hz, 2H), 6.76 (s, 1H), 2.41 (s, 3H).

1'-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (17). Spiro[isochromane-1,4'-piperidine] (250 mg, 1.23 mmol), 5-methyl-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazole-3-carbaldehyde (75) (332 mg, 1.23 mmol), and sodium triacetoxyborohydride (521 mg, 2.46 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound (300 mg, 51%). HRMS (ESI) m/z : calcd for $C_{25}H_{27}F_3N_3O_2$ [$M + H^+$], 458.2055; found, 458.2073. 1H NMR (400 MHz, $CDCl_3$): δ 7.52 (d, $J = 8.8$ Hz, 2H), 7.32

(d, $J = 8.8$ Hz, 2H), 7.23–7.08 (m, 4H), 6.26 (s, 1H), 3.92 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.66 (s, 2H), 2.88–2.83 (m, 4H), 2.54 (dd, $J = 11.3, 11.3$ Hz, 2H), 2.37 (s, 3H), 2.15–2.05 (m, 2H), 1.94 (d, $J = 12.9$ Hz, 2H).

Synthesis of 1'-((1-(6-Methoxy-pyridin-3-yl)-5-methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (18) (Scheme 1). Ethyl 1-(6-Methoxy-pyridin-3-yl)-5-methyl-1H-pyrazole-3-carboxylate (**68**). Ethyl 5-methyl-1H-pyrazole-3-carboxylate (**60**) (500 mg, 3.24 mmol), (6-methoxy-pyridin-3-yl)boronic acid (992 mg, 6.49 mmol), and copper acetate (884 mg, 4.86 mmol) were combined in DCM (10 mL) according to General Method 2. Work-up and purification afforded the title compound (340 mg, 38%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.23 (d, $J = 2.7$ Hz, 1H), 7.65 (dd, $J = 2.7, 8.8$ Hz, 1H), 6.85–6.81 (m, 2H), 4.26 (q, $J = 7.1$ Hz, 2H), 4.00 (s, 3H), 2.38 (s, 3H), 1.29 (dd, $J = 7.2, 7.2$ Hz, 3H).

1-(6-Methoxy-pyridin-3-yl)-5-methyl-1H-pyrazole-3-carbaldehyde (76). Ethyl 1-(6-methoxy-3-pyridyl)-5-methyl-1H-pyrazole-3-carboxylate (**68**) (380 mg, 1.45 mmol) and DIBAL (1 M in DCM) (3.64 mL, 3.64 mmol) were combined in DCM (10 mL) according to General Method 6a. Work-up and purification afforded the title compound (270 mg, 81%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 10.00 (s, 1H), 8.31–8.30 (m, 1H), 7.72 (dd, $J = 2.8, 8.8$ Hz, 1H), 6.92 (d, $J = 8.8$ Hz, 1H), 6.75 (s, 1H), 4.03 (s, 3H), 2.36 (s, 3H).

1'-((1-(6-Methoxy-pyridin-3-yl)-5-methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (18). Spiro[isochromane-1,4'-piperidine] (120 mg, 0.59 mmol), 1-(6-methoxy-3-pyridyl)-5-methyl-1H-pyrazole-3-carbaldehyde (**76**) (128 mg, 0.59 mmol), and sodium triacetoxyborohydride (250 mg, 1.18 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound (150 mg, 60%). HRMS (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{29}\text{N}_4\text{O}_2$ [$\text{M} + \text{H}^+$], 405.2288; found, 405.2292. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.25 (d, $J = 2.2$ Hz, 1H), 7.72 (dd, $J = 2.4, 8.8$ Hz, 1H), 7.23–7.09 (m, 4H), 6.85 (d, $J = 8.8$ Hz, 1H), 6.24 (s, 1H), 4.00 (s, 3H), 3.92 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.66 (s, 2H), 2.88–2.83 (m, 4H), 2.53 (dd, $J = 11.4, 11.4$ Hz, 2H), 2.32 (s, 3H), 2.15–2.06 (m, 2H), 1.93 (d, $J = 13.1$ Hz, 2H).

Synthesis of 1'-((1-(6-(Difluoromethoxy)pyridin-3-yl)-5-methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (19) (Scheme 1). 1'-[(5-methyl-1H-pyrazol-3-yl)methyl]spiro[isochromane-1,4'-piperidine] (**78**) (100 mg, 0.34 mmol), 2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (182 mg, 0.67 mmol), and copper acetate (92 mg, 0.50 mmol) were combined in DCM (3 mL) and pyridine (0.50 mL, 6.20 mmol) according to General Method 2. Work-up and purification afforded the title compound (10 mg, 6%). HRMS (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{27}\text{F}_2\text{N}_4\text{O}_2$ [$\text{M} + \text{H}^+$], 441.2102; found, 441.2108. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.32 (d, $J = 2.5$ Hz, 1H), 7.91 (dd, $J = 2.7, 8.7$ Hz, 1H), 7.23–7.02 (m, 5H), 6.27 (s, 1H), 3.92 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.66 (s, 2H), 2.85 (dd, $J = 5.5, 5.5$ Hz, 4H), 2.54 (dd, $J = 11.0, 11.0$ Hz, 2H), 2.36 (s, 3H), 2.14–2.07 (m, 2H), 1.93 (d, $J = 12.0$ Hz, 2H).

Synthesis of 1'-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (20) (Scheme 1). Ethyl 5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-3-carboxylate (**69**). [6-(Trifluoromethyl)-3-pyridyl]hydrazine (2.46 g, 13.91 mmol) and ethyl 2,4-dioxopentanoate (**59**) (2.20 g, 13.91 mmol) were dissolved in AcOH (20 mL) according to General Method 3b. Work-up

and purification afforded the title compound (2.70 g, 62%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.83 (d, $J = 2.4$ Hz, 1H), 8.01 (dd, $J = 2.1, 8.3$ Hz, 1H), 7.80 (d, $J = 8.3$ Hz, 1H), 6.93 (s, 1H), 4.30 (q, $J = 7.1$ Hz, 2H), 2.40 (s, 3H), 1.32 (dd, $J = 7.1, 7.1$ Hz, 3H).

5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-3-carbaldehyde (77). Ethyl 5-methyl-1-[6-(trifluoromethyl)-3-pyridyl]-1H-pyrazole-3-carboxylate (**69**) (1.45 mg, 4.85 mmol) and DIBAL (1 M in DCM) (12.11 mL, 12.11 mmol) were combined in DCM (10 mL) according to General Method 6a. Work-up and purification afforded the title compound (1.00 g, 77%). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 10.04 (s, 1H), 8.98 (d, $J = 2.3$ Hz, 1H), 8.13 (dd, $J = 2.2, 8.3$ Hz, 1H), 7.91 (d, $J = 8.4$ Hz, 1H), 6.82 (s, 1H), 2.51 (s, 3H).

1'-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (20). Spiro[isochromane-1,4'-piperidine] (40 mg, 0.20 mmol), 5-methyl-1-[6-(trifluoromethyl)-3-pyridyl]-1H-pyrazole-3-carbaldehyde (**77**) (50 mg, 0.20 mmol), and sodium triacetoxyborohydride (83 mg, 0.39 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (40 mg, 43%). HRMS (ESI) m/z : calcd for $\text{C}_{24}\text{H}_{26}\text{F}_3\text{N}_4\text{O}$ [$\text{M} + \text{H}^+$], 443.2058; found, 443.2039. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.93 (d, $J = 2.2$ Hz, 1H), 8.10 (dd, $J = 2.2, 8.5$ Hz, 1H), 7.82 (d, $J = 8.5$ Hz, 1H), 7.22–7.09 (m, 4H), 6.33 (s, 1H), 3.92 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.67 (s, 2H), 2.86 (dd, $J = 5.5, 5.5$ Hz, 4H), 2.59–2.51 (m, 2H), 2.48 (s, 3H), 2.15–2.03 (m, 2H), 1.93 (d, $J = 12.4$ Hz, 2H).

Synthesis of 2-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (21) (Scheme 1). Spiro[isochromane-1,4'-piperidine] (71 mg, 0.35 mmol), *tert*-butyl 2-(3-formyl-5-methyl-1H-pyrazol-1-yl)benzoate (100 mg, 0.35 mmol), and sodium triacetoxyborohydride (148 mg, 0.70 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded *tert*-butyl 2-(5-methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoate as a colorless gum (125 mg, 68%). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.91 (dd, $J = 1.7, 7.6$ Hz, 1H), 7.62–7.49 (m, 2H), 7.36 (d, $J = 7.6$ Hz, 1H), 7.25–7.09 (m, 3H), 5.32 (s, 1H), 4.72 (s, 1H), 3.90 (dd, $J = 5.5, 5.5$ Hz, 2H), 2.84 (dd, $J = 5.4, 5.4$ Hz, 2H), 2.57–2.56 (m, 1H), 2.18 (s, 4H), 1.93 (d, $J = 13.4$ Hz, 2H), 1.38 (d, $J = 3.2$ Hz, 12H), 1.30–1.25 (m, 1H). *tert*-Butyl 2-[5-methyl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)-1H-pyrazol-1-yl]benzoate (125 mg, 0.26 mmol) was then stirred in TFA (2 mL) at rt for 18 h and then concentrated *in vacuo*. The residue was loaded onto a 1 g SCX cartridge, eluting with 3 M NH_3/MeOH . The crude product was purified by preparative HPLC (XBridge column, 0.1% NH_4OH modifier) to afford the title compound (80 mg, 69%). HRMS (ESI) m/z : calcd for $\text{C}_{25}\text{H}_{28}\text{N}_3\text{O}_3$ [$\text{M} + \text{H}^+$], 418.2125; found, 418.2120. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.97 (dd, $J = 1.7, 7.4$ Hz, 1H), 7.55–7.45 (m, 2H), 7.36 (dd, $J = 1.4, 7.6$ Hz, 1H), 7.25–7.05 (m, 4H), 6.37 (s, 1H), 4.01 (s, 2H), 3.81 (dd, $J = 5.4, 5.4$ Hz, 2H), 3.34 (dd, $J = 2.1, 9.1$ Hz, 2H), 3.07 (dd, $J = 11.6, 11.6$ Hz, 2H), 2.79 (dd, $J = 5.3, 5.3$ Hz, 2H), 2.58–2.49 (m, 2H), 2.31 (s, 3H), 1.92 (d, $J = 14$ Hz, 2H).

Synthesis of 3-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (22) (Scheme 2). 3-(3-(Ethoxycarbonyl)-5-methyl-1H-pyrazol-1-yl)benzoic Acid (**87**). Ethyl 2,4-dioxopentanoate (**79**) (10.29 g, 65.07 mmol) was dissolved in EtOH (100 mL) and 3-hydrazinobenzoic acid (9.90 g, 65.07 mmol) was added. The

reaction was heated to reflux for 1 h and then allowed to cool to rt. The solvent was removed *in vacuo* and H₂O was added. The product was extracted with EtOAc, dried (hydrophobic frit), and concentrated *in vacuo* to afford a mixture of isomers (approximately 1:4 in favor of the desired isomer) (16.48 g, 60 mmol total). No attempt was made to separate the regioisomers at this stage, and the crude material was taken through to the next step without further purification. LCMS (ESI+) *m/z*: 275 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.20–8.12 (m, 2H), 7.74 (d, *J* = 8.0, 1H), 7.59 (t, *J* = 7.8, 1H), 6.76 (s, 1H), 4.41 (q, *J* = 7.1, 2H), 1.39 (t, *J* = 7.1, 3H).

Ethyl 1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate (93). A mixture of 3-(3-ethoxycarbonyl-5-methyl-1H-pyrazol-1-yl)benzoic acid and 3-(5-ethoxycarbonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid (**87**) (5.00 g, 18.23 mmol in total as a mixture of isomers) was dissolved in thionyl chloride (3.99 mL, 54.69 mmol), and three drops of pyridine were added. The mixture was heated to 50 °C for 1 h and then allowed to cool to rt. The mixture was concentrated *in vacuo* and the resulting oil was dissolved in DCM (20 mL). Ethanolamine (2.19 mL, 36.46 mmol) was added dropwise and the mixture was stirred for 3 h at rt. Further, thionyl chloride (3.99 mL, 54.69 mmol) was added to convert the OH to Cl. This mixture was stirred at rt for 18 h. The reaction was quenched with the dropwise addition of H₂O. The aqueous layer was basified with 2 M NaOH and extracted with DCM. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford a brown oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer. This solid was dissolved in THF, cooled to 0 °C, and sodium hydride (60% in mineral oil) (729 mg, 18.23 mmol) was added. The reaction mixture was allowed to warm to rt and stirred for 2 h. The reaction was quenched carefully with water at 0 °C. The volatiles were removed *in vacuo* and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (2.1 g, 38%). LCMS (ESI) *m/z*: 300 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.03–7.98 (m, 2H), 7.60 (d, *J* = 7.9 Hz, 1H), 7.52 (t, *J* = 7.9 Hz, 1H), 6.73 (s, 1H), 4.48–4.36 (m, 4H), 4.07 (t, *J* = 9.5 Hz, 2H), 2.34 (s, 3H), 1.39 (t, *J* = 7.0 Hz, 3H).

1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazole-3-carbaldehyde (99). Ethyl 1-[3-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (**93**) (2.10 g, 7.02 mmol) and DIBAL (1 M in DCM) (17.54 mL, 17.54 mmol) were combined in DCM (20 mL) with MnO₂ (6.10 g, 70.16 mmol) added in the second step according to General Method 5b. Work-up and purification afforded the title compound, which was used without further purification.

1'-((1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (105). Spiro[isochromane-1,4'-piperidine] (80 mg, 0.39 mmol), 1-[3-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carbaldehyde (**99**) (100 mg, 0.39 mmol), and sodium triacetoxyborohydride (166 mg, 0.78 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (30 mg, 16%). LCMS (ESI) *m/z*: 442 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 8.02 (s, 1H), 7.94 (d, *J* = 7.5 Hz, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.50 (t, *J* = 7.9 Hz, 1H), 7.24–7.10 (m, 3H), 7.08 (d, *J* = 7.5 Hz, 1H), 6.24 (s, 1H), 4.45 (t, *J* = 9.5 Hz, 2H), 4.08 (t, *J* = 9.5 Hz, 2H), 3.92–3.87 (m, 2H), 3.66 (s, 2H), 2.89–

2.79 (m, 4H), 2.53 (t, *J* = 11.6 Hz, 2H), 2.36 (s, 3H), 2.09 (t, *J* = 13.3 Hz, 2H), 1.91 (d, *J* = 13.3 Hz, 2H).

3-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-yl-methyl)-1H-pyrazol-1-yl)benzoic Acid (22). 1'-[[1-[3-(4,5-Dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazol-3-yl]-methyl]spiro[isochromane-1,4'-piperidine] (**105**) (30 mg, 0.07 mmol) was dissolved in 3 M HCl according to General Method 3. Work-up and purification afforded the title compound (19 mg, 66%). LCMS (ESI) *m/z*: 418 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₅H₂₈N₃O₃ [M + H]⁺, 418.2130; found, 418.2133. ¹H NMR (400 MHz, CDCl₃): δ 8.24–8.16 (m, 2H), 7.53 (d, *J* = 4.2 Hz, 2H), 7.21–7.02 (m, 4H), 6.44 (s, 1H), 4.17 (s, 2H), 3.88–3.83 (m, 2H), 3.44 (d, *J* = 10.9 Hz, 2H), 3.13–3.03 (m, 2H), 2.82–2.76 (m, 2H), 2.53 (t, *J* = 13.3 Hz, 2H), 2.32 (s, 3H), 1.98 (d, *J* = 14.3 Hz, 2H).

Synthesis of 4-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-yl)methyl)-1H-pyrazol-1-yl)benzoic Acid (23) (Scheme 2). **4-(3-(Ethoxycarbonyl)-5-methyl-1H-pyrazol-1-yl)benzoic Acid (88).** Ethyl 2,4-dioxopentanoate (10.39 g, 65.73 mmol) was dissolved in EtOH (100 mL) and 4-hydrazinobenzoic acid (**80**) (10.0 g, 65.73 mmol) was added. The reaction mixture was heated to reflux for 2 h and then allowed to cool to rt. The solvent was removed *in vacuo*, H₂O was added, and the product was extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford a mixture of isomers (approximately 1:4 in favor of the desired isomer) 4-(5-ethoxycarbonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid and 4-(3-ethoxycarbonyl-5-methyl-1H-pyrazol-1-yl)benzoic acid. No attempt was made to separate the regioisomers at this stage and the crude material was taken onto the next step without further purification. LCMS (ESI) *m/z*: 275 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.24 (d, *J* = 8.3, 2H), 7.63 (d, *J* = 8.3, 2H), 6.78 (s, 1H), 4.43 (q, *J* = 7.1, 2H), 2.41 (s, 3H), 1.41 (t, *J* = 7.1, 3H) (major isomer reported).

Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazole-3-carboxylate (94). A mixture of 4-(3-ethoxycarbonyl-5-methyl-1H-pyrazol-1-yl)benzoic acid and 4-(5-ethoxycarbonyl-3-methyl-1H-pyrazol-1-yl)benzoic acid (**88**) (18.82 g, 68.62 mmol in total as a mixture of isomers) was dissolved in thionyl chloride (20.02 mL, 274.48 mmol), and three drops of pyridine were added. The mixture was heated to 50 °C for 2 h and then allowed to cool to rt. The mixture was concentrated *in vacuo*, and the resulting oil was dissolved in DCM (20 mL). Ethanolamine (8.26 mL, 137.24 mmol) was added dropwise and the mixture was stirred for 3 h at rt. Further thionyl chloride (20.01 mL, 274.48 mmol) was added to convert the OH to Cl. This mixture was stirred at rt for 18 h. The reaction was quenched with the dropwise addition of H₂O. The aqueous layer was basified with 2 M NaOH and extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford a brown oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (10.62 g, 44%). LCMS (ESI) *m/z*: 336 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.91 (d, *J* = 8.1 Hz, 2H), 7.57 (d, *J* = 8.1 Hz, 2H), 6.75 (s, 1H), 4.42 (q, *J* = 7.1 Hz, 2H), 3.86–3.80 (m, 2H), 3.79–3.74 (m, 2H), 2.37 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (10.62 g, 31.63 mmol) was dissolved in THF (50 mL) and cooled to 0 °C. NaH (759 mg, 31.63 mmol) was added portionwise waiting for

the effervescence to cease each time. The reaction was allowed to stir at 0 °C for 3 h and then carefully quenched by adding H₂O dropwise. The mixture was allowed to warm to rt and TBME was added. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound, which was used without further purification. LCMS (ESI) *m/z*: 300 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.06 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 6.75 (s, 2H), 4.47 (t, *J* = 9.6 Hz, 2H), 4.42 (q, *J* = 7.1, 2H), 4.09 (t, *J* = 9.6 Hz, 2H), 2.37 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H).

1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazole-3-carbaldehyde (100). Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carboxylate (**94**) (9.75 g, 32.57 mmol) and DIBAL (1 M in DCM) (6.51 mL, 6.51 mmol) were combined in DCM (90 mL) with MnO₂ (14.16 g, 162.87 mmol) added in second step according to General Method 5b. Work-up and purification afforded the title compound (5.14 g, 59%). LCMS (ESI) *m/z*: 256 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 10.00 (s, 1H), 8.11 (d, *J* = 8.5 Hz, 2H), 7.56 (d, *J* = 8.5 Hz, 2H), 6.73 (s, 1H), 4.48 (t, *J* = 9.5 Hz, 2H), 4.10 (t, *J* = 9.5 Hz, 2H), 2.40 (s, 3H).

1'-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (106). Spiro[isochromane-1,4'-piperidine] (1.79 g, 8.81 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carbaldehyde (**100**) (2.5 g, 8.81 mmol), and sodium triacetoxyborohydride (3.74 g, 17.63 mmol) were combined in DCM (4 mL) according to General Method 1. The crude material was purified by flash chromatography on a KPNH column (eluting with 10–50% EtOAc in heptane) to afford the title compound (1.99 g, 48%). LCMS (ESI) *m/z*: 443 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.03 (d, *J* = 8.5 Hz, 2H), 7.54 (d, *J* = 8.5 Hz, 2H), 7.22–7.15 (m, 2H), 7.13 (t, *J* = 7.3 Hz, 1H), 7.08 (d, *J* = 7.3 Hz, 1H), 6.24 (s, 1H), 4.46 (t, *J* = 9.5 Hz, 2H), 4.09 (t, *J* = 9.5 Hz, 2H), 3.92–3.87 (m, 2H), 3.65 (s, 2H), 2.87–2.80 (m, 4H), 2.52 (t, *J* = 11.8 Hz, 2H), 1.90 (d, *J* = 13.4 Hz, 2H).

4-(5-Methyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (23). 1'-[1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-methyl-1H-pyrazol-3-yl]-methylspiro[isochromane-1,4'-piperidine] (**106**) (1.9 g, 4.29 mmol) was dissolved in 3 M HCl according to General Method 4. Work-up and purification afforded the title compound (1 g, 55%). LCMS (ESI) *m/z*: 418 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₅H₂₈N₃O₃ [M + H]⁺, 418.2130; found, 418.2159. ¹H NMR (400 MHz, CD₃OD): δ 8.11 (d, *J* = 8.1 Hz, 2H), 7.52 (d, *J* = 8.1 Hz, 2H), 7.24–7.11 (m, 4H), 6.48 (s, 1H), 4.30 (s, 1H), 3.94 (t, *J* = 5.4 Hz, 2H), 3.45 (d, *J* = 11.4 Hz, 2H), 3.36 (d, *J* = 12.5 Hz, 2H), 2.87–2.80 (m, 2H), 2.40 (s, 3H), 2.31 (td, *J* = 13.7, 3.8 Hz, 2H), 2.11 (d, *J* = 14.6 Hz, 2H).

Synthesis of 4-(5-Ethyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (24) (Scheme 2). Lithium 4-(3-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)benzoate (**87**). 4-Aminobenzoic acid (2.00 g, 14.58 mmol) was suspended in H₂O (30 mL) and cooled to 0 °C. Concentrated H₂SO₄ (15 mL, 14.58 mmol) was added dropwise to this suspension, followed by the dropwise addition of NaNO₂ (5% aqueous solution) (20 mL, 14.58 mmol). The reaction mixture was stirred for 30 min at 0 °C, then NaBF₄ (17% aqueous solution) (12 mL, 14.58 mmol) was added, and the reaction was stirred for further 30 min. A solution of ethyl 2-chloro-3-oxo-butanoate (2.40 g, 14.58 mmol) in MeOH (75 mL) was added to the reaction mixture, which was then allowed to warm

to rt and stirred for 3 h. The resulting precipitate was filtered, washed with H₂O, and air-dried to afford (E)-4-(2-(1-chloro-2-ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid (3.00 g, 72%). ¹H NMR (400 MHz, DMSO): δ 12.65–12.65 (m, 1H), 10.84 (s, 1H), 7.92 (d, *J* = 8.7 Hz, 2H), 7.43 (d, *J* = 8.7 Hz, 2H), 4.32 (q, *J* = 7.1 Hz, 2H), 1.31 (dd, *J* = 7.1, 7.1 Hz, 3H). (E)-4-(2-(1-Chloro-2-ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid (1.30 g, 4.80 mmol) and 1-diethoxyphosphorylbutan-2-one (1.00 g, 4.80 mmol) were mixed in diglyme (15 mL) and LiOH (504 mg, 12.01 mmol) was added. The reaction mixture was stirred at rt for 18 h. The reaction mixture was concentrated *in vacuo* to afford the title compound and was used directly in the next step without further purification.

Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-ethyl-1H-pyrazole-3-carboxylate (95). Lithium 4-(3-ethoxycarbonyl-5-ethyl-1H-pyrazol-1-yl)benzoate (**89**) (1.40 g, 4.76 mmol) was mixed in thionyl chloride (3 mL, 18.66 mmol) and heated to reflux for 2 h. The reaction mixture was allowed to cool to rt and then concentrated *in vacuo*. The resulting orange solid was suspended in DCM (20 mL) and cooled to 0 °C. 2-Chloroethanamine hydrochloride (607 mg, 5.23 mmol) and DIPEA (3.32 mL, 19.03 mmol) were added, and the reaction mixture was allowed to warm up to rt for 18 h. The reaction was quenched with H₂O, passed through a hydrophobic frit, and concentrated *in vacuo*. The crude material was purified by flash chromatography (eluting with 0–100% EtOAc in heptane) to afford ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-ethyl-1H-pyrazole-3-carboxylate (1.00 g, 57%). ¹H NMR (400 MHz, CDCl₃): δ 7.93 (d, *J* = 8.6 Hz, 2H), 7.58 (d, *J* = 8.6 Hz, 2H), 6.82 (s, 1H), 6.67 (d, *J* = 5.0 Hz, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 3.88–3.78 (m, 4H), 2.71 (q, *J* = 7.5 Hz, 2H), 1.43 (dd, *J* = 7.1, 7.1 Hz, 3H), 1.30–1.25 (m, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-ethyl-1H-pyrazole-3-carboxylate (1.00 g, 2.86 mmol) was dissolved in THF (30 mL) and cooled to 0 °C. NaH (126 mg, 3.14 mmol) was added, and the reaction mixture was allowed to warm to rt for 18 h and then heated to 50 °C for 1 h. The reaction was allowed to cool to rt and then quenched with H₂O. The volatiles were removed *in vacuo*, and the product was extracted with EtOAc. The combined organics were washed with brine, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (820 mg, 87%). ¹H NMR (400 MHz, CDCl₃): δ 8.09 (d, *J* = 8.6 Hz, 2H), 7.54 (d, *J* = 8.7 Hz, 2H), 6.81 (s, 1H), 4.53–4.42 (m, 4H), 4.12 (dd, *J* = 9.5, 9.5 Hz, 2H), 2.71 (q, *J* = 7.4 Hz, 2H), 1.43 (dd, *J* = 7.1, 7.1 Hz, 3H), 1.27 (dd, *J* = 7.5, 7.5 Hz, 3H).

1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-ethyl-1H-pyrazole-3-carbaldehyde (101). Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-ethyl-1H-pyrazole-3-carboxylate (**95**) (820 mg, 2.62 mmol) and DIBAL (1 M in DCM) (6.54 mL, 6.54 mmol) were combined in DCM (25 mL) according to General Method 5a. Work-up and purification afforded the title compound (600 mg, 81%). ¹H NMR (400 MHz, CDCl₃): δ 10.03 (s, 1H), 8.13 (d, *J* = 8.6 Hz, 2H), 7.57 (d, *J* = 8.7 Hz, 2H), 6.80 (s, 1H), 4.51 (dd, *J* = 9.5, 9.5 Hz, 2H), 4.14 (dd, *J* = 9.5, 9.5 Hz, 2H), 2.74 (q, *J* = 7.5 Hz, 2H), 1.28 (dd, *J* = 7.5, 7.5 Hz, 3H).

4-(5-Ethyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (24). Spiro[isochromane-1,4'-piperidine] (175 mg, 0.86 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-ethyl-1H-pyrazole-3-carbaldehyde (**101**) (232 mg, 0.86 mmol), and sodium triacetoxyborohydride (365 mg, 1.72 mmol) were combined in DCM (5 mL) according to General Method 1. The crude oxazoline

intermediate was dissolved in 3 M HCl (3 mL) according to General Method 3. Work-up and purification afforded 4-[5-ethyl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)-1H-pyrazol-1-yl]benzoic acid (200 mg, 51%). LCMS (ESI) m/z : 432.2 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 8.13 (d, J = 8.5 Hz, 2H), 7.37–7.30 (m, 2H), 7.22–7.10 (m, 4H), 6.37 (s, 1H), 4.09 (s, 2H), 3.94 (dd, J = 5.4, 5.4 Hz, 2H), 3.48–3.48 (m, 2H), 3.05 (dd, J = 11.4, 11.4 Hz, 2H), 2.87 (dd, J = 5.2, 5.2 Hz, 2H), 2.73–2.58 (m, 4H), 2.04 (d, J = 13.7 Hz, 2H), 1.19 (dd, J = 7.5, 7.5 Hz, 3H).

Synthesis of 4-(5-Isopropyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (25) (Scheme 2). 1,1-Diethoxy-5-methyl-hexane-2,4-dione (81). Ethyl 2,2-diethoxyacetate (4.2 mL, 23 mmol) was added portionwise to a solution of 3-methylbutan-2-one (2 g, 23 mmol) in toluene (10 mL) at 0 °C. NaH (60% dispersion, 2.5 mL, 46 mmol) was added portionwise, and the mixture was stirred at 0 °C for 2 h. H₂O was added dropwise until the reaction was quenched, followed by 3 M HCl solution, dropwise, until the solution was pH 5. The organics were extracted with DCM, passed through a hydrophobic frit, and concentrated *in vacuo* to afford the title compound, which was used in the next step with no further purification.

4-(3-Formyl-5-isopropyl-1H-pyrazol-1-yl)benzoic Acid (84). 1,1-Diethoxy-5-methyl-hexane-2,4-dione (83) (386 mg, 1.78 mmol) and 4-hydrazinobenzoic acid (80) (272 mg, 1.78 mmol) were dissolved in EtOH (2 mL) and H₂O (2 mL). The mixture was stirred at 35 °C for 18 h and then allowed to cool to rt and concentrated *in vacuo* to afford an orange solid. The crude material was triturated with Et₂O and filtered to afford the title compound (349 mg, 72%). LCMS (ESI) m/z : 259 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 10.01 (s, 1H), 8.30 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 8.6 Hz, 2H), 6.81 (s, 1H), 3.11 (sept, J = 6.8 Hz, 1H), 1.23 (d, J = 6.8 Hz, 6H).

4-(5-Isopropyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (25). Spiro[isochromane-1,4'-piperidine] (39 mg, 0.19 mmol), 4-(3-formyl-5-isopropyl-1H-pyrazol-1-yl)benzoic acid (84) (50 mg, 0.19 mmol), and sodium triacetoxyborohydride (82 mg, 0.39 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (20 mg, 23%). LCMS (ESI) m/z : 446 (M + H)⁺. HRMS (ESI) m/z : calcd for C₂₇H₃₂N₃O₃ [M + H]⁺, 446.2443; found, 446.2423. ¹H NMR (500 MHz, CDCl₃): δ 8.08 (d, J = 8.4 Hz, 2H), 7.30–7.26 (m, 3H), 7.18 (td, J = 7.4, 1.4 Hz, 1H), 7.14 (td, J = 7.4, 1.4 Hz, 1H), 7.09 (d, J = 7.4 Hz, 1H), 6.30 (s, 1H), 4.03 (s, 2H), 3.92 (t, J = 5.5 Hz, 2H), 3.48 (d, J = 10.5 Hz, 2H), 3.09–2.98 (m, 3H), 2.85 (t, J = 5.4 Hz, 2H), 2.66–2.57 (m, 2H), 2.03 (d, J = 13.8 Hz, 2H), 1.11 (d, J = 6.8 Hz, 6H).

Synthesis of 4-(5-(tert-Butyl)-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (26) (Scheme 2). 4-(5-(tert-Butyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)benzoic Acid (90). Ethyl 5,5-dimethyl-2,4-dioxohexanoate (2.00 g, 9.99 mmol) was dissolved in EtOH (20 mL) and 4-hydrazinobenzoic acid (80) (1.52 g, 9.99 mmol) was added. The mixture was heated to reflux for 1 h and then allowed to cool to rt, and the solvent was removed *in vacuo*. H₂O was added and the product was extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (3.12 g, 99%). LCMS (ESI) m/z : 317 (M + H)⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.21 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H),

6.79 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 2H), 1.21 (s, 9H).

Ethyl 5-(tert-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1H-pyrazole-3-carboxylate (96). 4-(5-tert-Butyl-3-ethoxycarbonyl-1H-pyrazol-1-yl)benzoic acid (90) (3.12 g, 9.86 mmol) was dissolved in DCM (20 mL), and HOBt (1.60 g, 11.84 mmol), EDC.HCl (2.27 g, 11.84 mmol), DIPEA (6.87 mL, 39.45 mmol), and 2-chloroethanamine hydrochloride (1.37 g, 11.84 mmol) were added. The reaction was stirred at rt for 1 h. The reaction mixture was washed with H₂O extracting with further DCM. The organics were dried (hydrophobic frit) and the solvent was removed *in vacuo* to afford an orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford ethyl 5-tert-butyl-1-[4-(2-chloroethylcarbamoyl)phenyl]-1H-pyrazole-3-carboxylate (1.76 g, 47%). LCMS (ESI) m/z : 378 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 6.90–6.38 (m, 1H), 6.76 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 3.85–3.79 (m, 2H), 3.78–3.73 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.19 (s, 9H). Ethyl 5-tert-butyl-1-[4-(2-chloroethylcarbamoyl)phenyl]-1H-pyrazole-3-carboxylate (1.76 g, 4.66 mmol) was dissolved in THF (20 mL) and cooled to 0 °C. NaH (186 mg, 4.66 mmol) was then added, and the reaction mixture was stirred at 0 °C for 1 h. H₂O was added carefully to quench the reaction, and the volatiles were removed *in vacuo*. The product was extracted with TBME, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (1.00 g, 63%). LCMS (ESI) m/z : 342 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 8.04 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 6.76 (s, 1H), 4.48 (t, J = 9.5 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 4.10 (t, J = 9.5 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H), 1.19 (s, 9H).

5-(tert-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1H-pyrazole-3-carbaldehyde (102). Ethyl 5-tert-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazole-3-carboxylate (96) (1.00 g, 2.93 mmol) and DIBAL (1 M in DCM) (6.51 mL, 6.51 mmol) were combined in DCM (5 mL) with MnO₂ (2.55 g, 29.29 mmol) added in the second step according to General Method 5b. Work-up and purification afforded the title compound (624 mg, 68%). LCMS (ESI) m/z : 298 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 9.95 (s, 1H), 8.10 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 6.75 (s, 1H), 4.50 (t, J = 9.5 Hz, 2H), 4.12 (t, J = 9.6 Hz, 2H), 1.20 (s, 9H).

1'-((5-(tert-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (107). Spiro[isochromane-1,4'-piperidine] (41 mg, 0.20 mmol), 5-tert-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazole-3-carbaldehyde (102) (60 mg, 0.20 mmol), and sodium triacetoxyborohydride (86 mg, 0.40 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (41 mg, 40%). LCMS (ESI) m/z : 485 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.02 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 7.22 (d, J = 7.7 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.13 (td, J = 7.3 Hz, 1.3, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.22 (s, 1H), 4.47 (t, J = 9.6 Hz, 2H), 4.10 (t, J = 9.6 Hz, 2H), 3.90 (t, J = 5.5 Hz, 2H), 3.61 (s, 2H), 2.88–2.80 (m, 4H), 2.50 (t, J = 12.1 Hz, 2H), 2.09 (td, J = 13.1, 4.3 Hz, 2H), 1.90 (d, J = 13.1 Hz, 2H), 1.18 (s, 9H).

4-(5-(tert-Butyl)-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (26). 1'-[[5-tert-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazol-3-yl]-methyl]spiro[isochromane-1,4'-piperidine] (107) (41 mg, 0.08

mmol) was dissolved in 3 M HCl according to General Method 4. Work-up and purification afforded the title compound (15 mg, 37%). LCMS (ESI) *m/z*: 459 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₈H₃₄N₃O₃ [M + H]⁺, 460.2600; found, 460.2613. ¹H NMR (500 MHz, *d*⁶-DMSO): δ 8.05 (d, *J* = 8.3 Hz, 2H), 7.52 (d, *J* = 8.3 Hz, 2H), 7.22 (d, *J* = 7.4 Hz, 1H), 7.17 (t, *J* = 7.4 Hz, 1H), 7.13 (t, *J* = 7.4 Hz, 1H), 7.09 (*J* = 7.4 Hz, 1H), 6.25 (s, 1H), 3.85–3.80 (m, 2H), 3.53 (br s, 2H), 2.83–2.71 (m, 4H), 2.47–2.39 (m, 2H), 2.01–1.91 (m, 2H), 1.81 (d, *J* = 13.1 Hz, 2H), 1.14 (s, 9H).

Synthesis of 4-(5-(Difluoromethyl)-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (27) (Scheme 2). 4-(5-(Difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)benzoic Acid (91). Ethyl 5,5-difluoro-2,4-dioxo-pentanoate (2.5 g, 12.88 mmol) was dissolved in EtOH (20 mL) and AcOH (5 mL) and 4-hydrazinobenzoic acid (80) (1.96 g, 12.88 mmol) was added. The reaction was heated to reflux for 18 h and then allowed to cool to rt, and the solvent was removed *in vacuo*. H₂O was added, and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (4.45 g, 100% in total as a mixture of isomers) and used in the next step without further purification.

5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazole-3-carbaldehyde (97). A mixture of 4-[5-(difluoromethyl)-3-ethoxycarbonyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(difluoromethyl)-5-ethoxycarbonyl-1H-pyrazol-1-yl]benzoic acid (91) (4.45 g, 14.34 mmol in total as a mixture of isomers) was dissolved in DCM (50 mL) and HOBt (2.87 g, 21.23 mmol), EDC.HCl (3.30 g, 17.21 mmol), DIPEA (7.49 mL, 43.03 mmol), and 2-chloroethanamine hydrochloride (2.00 g 17.21 mmol) were added. The reaction was stirred at rt for 18 h. H₂O was added, extracting with further DCM. The combined organics were dried (hydrophobic frit), and the solvent was removed *in vacuo* to afford a dark orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1H-pyrazole-3-carboxylate (470 mg, 9%). ¹H NMR (500 MHz, CDCl₃): δ 7.94 (d, *J* = 8.6 Hz, 2H), 7.65 (d, *J* = 8.6 Hz, 2H), 7.27 (s, 1H), 6.65 (t, *J* = 53.5 Hz, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 3.87–3.81 (m, 2H), 3.79–3.75 (m, 2H), 1.41 (t, *J* = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1H-pyrazole-3-carboxylate (470 mg, 1.26 mmol) was dissolved in THF (25 mL), cooled to 0 °C, and NaH (202 mg, 5.06 mmol) was added. The reaction was stirred for 2 h at 0 °C and then quenched by the dropwise addition of H₂O. The mixture was allowed to warm to rt, and the volatiles were removed *in vacuo*. The pH was carefully adjusted to pH 6 using 3 M HCl, and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated *in vacuo* to afford a yellow oil. The aqueous phase was also concentrated *in vacuo* and combined with the material obtained from the EtOAc extraction to afford the title compound, which was used in the next step without further purification.

5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-pyrazole-3-carbaldehyde (103). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1H-pyrazole-3-carboxylate (97) and DIBAL (1 M in DCM) (2.77 mL, 2.77 mmol) were combined in DCM (30 mL) with MnO₂ (1.20 g, 13.83 mmol) added in the second step according to General Method Sb. Further, DIBAL (1 M in DCM) (2.77 mL, 2.77 mmol) was needed in this case for reaction completion and

oxidation with MnO₂ only required 2 h for completion before formation of side products. Work-up and purification afforded the title compound (148 mg, 35%). LCMS (ESI) *m/z*: 292 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 10.07 (s, 1H), 8.14 (d, *J* = 8.7 Hz, 2H), 7.62 (d, *J* = 8.7 Hz, 2H), 6.68 (t, *J* = 53.5 Hz, 1H), 4.50 (t, *J* = 9.6 Hz, 2H), 4.12 (t, *J* = 9.6 Hz, 2H).

1'-((5-(Difluoromethyl)-1-(4-(4,5-dihydrooxazol-2-yl)-phenyl)-1H-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (108). Spiro[isochromane-1,4'-piperidine] (52 mg, 0.25 mmol), 5-(difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)-phenyl]-1H-pyrazole-3-carbaldehyde (103) (74 mg, 0.25 mmol), and sodium triacetoxylborohydride (108 mg, 0.51 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (45 mg, 37%). LCMS (ESI) *m/z*: 479 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.07 (d, *J* = 8.7 Hz, 2H), 7.58 (d, *J* = 8.7 Hz, 2H), 7.22–7.16 (m, 2H), 7.16–7.12 (m, 1H), 7.08 (d, *J* = 7.5 Hz, 1H), 6.80 (s, 1H), 6.66 (t, *J* = 53.5 Hz, 1H), 4.47 (t, *J* = 9.6 Hz, 2H), 4.10 (t, *J* = 9.6 Hz, 2H), 3.90 (t, *J* = 5.5 Hz, 2H), 3.71 (s, 2H), 2.85–2.80 (m, 4H), 2.53 (t, *J* = 12.0 Hz, 2H), 2.08 (td, *J* = 13.4, 4.3 Hz, 2H), 1.91 (d, *J* = 13.4 Hz, 2H).

4-(5-(Difluoromethyl)-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (27). 1'-[[5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1H-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (108) (45 mg, 0.09 mmol) was dissolved in 3 M HCl (3 mL) according to General Method 3. Work-up and purification afforded 4-[5-(difluoromethyl)-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)-1H-pyrazol-1-yl]benzoic acid (19 mg, 44%). LCMS (ESI) *m/z*: 454 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₅H₂₆F₂N₃O₃ [M + H]⁺, 454.1916; found, 454.1929. ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 2H), 7.23 (d, *J* = 7.7 Hz, 1H), 7.20–7.13 (m, 2H), 7.09 (d, *J* = 7.3 Hz, 1H), 6.77 (s, 1H), 6.64 (t, *J* = 53.5 Hz, 1H), 4.02 (s, 2H), 3.96–3.91 (m, 2H), 3.43 (d, *J* = 10.0 Hz, 2H), 2.98 (t, *J* = 11.9 Hz, 2H), 2.88–2.82 (m, 2H), 2.52 (t, *J* = 13.5 Hz, 2H), 2.03 (d, *J* = 13.5 Hz, 2H).

Synthesis of 4-(3-(Spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic Acid (28) (Scheme 2). 4-(3-(Ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic Acid (92). 4-Hydrazinobenzoic acid (80) (1.43 g, 9.43 mmol) and ethyl 5,5,5-trifluoro-2,4-dioxo-pentanoate (2.00 g, 9.43 mmol) were dissolved in EtOH (20 mL) and AcOH (5 mL) according to General Method 3a. Work-up and purification afforded the title compound, which was used in the next step with no further purification. LCMS (ESI) *m/z*: 329 (M + H)⁺. ¹H NMR (500 MHz, CD₃OD): δ 7.95 (d, *J* = 9.0 Hz, 2H), 7.65 (d, *J* = 9.0 Hz, 2H), 4.34 (q, *J* = 7.1 Hz, 2H), 1.37 (t, *J* = 7.1 Hz, 3H).

Ethyl 1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (98). 4-[3-ethoxycarbonyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzoic acid (92) (3.97 g, 12.10 mmol) was dissolved in DCM (20 mL), and EDC.HCl (2.78 g, 14.51 mmol), DIPEA (6.25 mg, 48.38 mmol), HOBt (1.96 g, 14.51 mmol), and 2-chloroethanamine hydrochloride (1.68 g, 14.51 mmol) were added. The reaction was stirred at rt overnight. H₂O was then added and the mixture was passed through a hydrophobic frit. The solvent was removed *in vacuo* to afford a dark orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second fraction to elute afforded the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (467 mg, 10%). LCMS (ESI) *m/z*: 390 (M

+ H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.42 (d, *J* = 9.0 Hz, 2H), 7.35 (d, *J* = 9.0 Hz, 2H), 4.33 (q, *J* = 7.1 Hz, 2H), 3.67–3.58 (m, 4H), 1.36 (t, *J* = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1*H*-pyrazole-3-carboxylate (467 mg, 1.20 mmol) was dissolved in THF (25 mL) and cooled to 0 °C. Sodium hydride (197 mg, 4.92 mmol) was added, and the reaction was stirred at 0 °C for 1 h, allowed to warm to rt for 2 h, and then heated to reflux for 1 h. The mixture was allowed to cool to rt and was quenched with H₂O dropwise. The reaction mixture was concentrated *in vacuo* to afford the title compound, which was used without further purification.

1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1*H*-pyrazole-3-carbaldehyde (104). Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1*H*-pyrazole-3-carboxylate (**98**) and DIBAL (1 M in DCM) (3.00 mL, 3.00 mmol) were combined in DCM (50 mL) according to General Method 6b. Further DIBAL (1 M in DCM) (1.20 mL, 1.20 mmol) was added in this case, but the reaction was not pushed to completion. LiAlH₄ (1.20 mL, 1.20 mmol) was therefore added and the reaction was allowed to warm to rt for 18 h before adding further LiAlH₄ (1.20 mL, 1.20 mmol) and stirring at rt for 2 h. MnO₂ (1.04 g, 11.99 mmol) was added in the second step according to General Method 6b. Work-up and purification afforded the title compound as a colorless oil (45 mg, 12%). LCMS (ESI) *m/z*: 310 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 10.06 (s, 1H), 8.13 (d, *J* = 8.7 Hz, 2H), 7.59 (d, *J* = 8.7 Hz, 2H), 5.30 (s, 1H), 4.50 (t, *J* = 9.6 Hz, 2H), 4.12 (t, *J* = 9.6 Hz, 2H).

1'-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-(trifluoromethyl)-1*H*-pyrazol-3-yl)methyl)spiro[isochromane-1,4'-piperidine] (109). Spiro[isochromane-1,4'-piperidine] (30 mg, 0.15 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1*H*-pyrazole-3-carbaldehyde (**104**) (45 mg, 0.15 mmol), and sodium triacetoxyborohydride (62 mg, 0.29 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (32 mg, 44%). LCMS (ESI) *m/z*: 497 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 8.08–8.04 (m, 2H), 7.56 (d, *J* = 8.6 Hz, 2H), 7.22–7.17 (m, 2H), 7.16–7.13 (m, 1H), 7.09 (d, *J* = 7.5 Hz, 1H), 6.87 (s, 1H), 4.47 (t, *J* = 9.6 Hz, 2H), 4.10 (t, *J* = 9.6 Hz, 2H), 3.90 (t, *J* = 5.5 Hz, 2H), 3.70 (s, 2H), 2.85–2.78 (m, 2H), 2.54 (t, *J* = 11.7 Hz, 2H), 2.08 (td, *J* = 13.2, 3.7 Hz, 2H), 1.92 (d, *J* = 13.7 Hz, 2H).

4-(3-(Spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-5-(trifluoromethyl)-1*H*-pyrazol-1-yl)benzoic Acid (28). 1'-[[1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (**109**) (32 mg, 0.06 mmol) was dissolved in 3 M HCl according to General Method 4. Work-up afforded no product. The aqueous phase was concentrated *in vacuo* and purified by preparative HPLC (XBridge column, 0.1% NH₄OH modifier) to afford the title compound (5 mg, 66%). LCMS (ESI) *m/z*: 472 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₅H₂₅F₃N₃O₃ [M + H]⁺, 472.1848; found, 472.1851. ¹H NMR (500 MHz, CDCl₃): δ 8.46 (d, *J* = 8.5 Hz, 2H), 7.95 (d, *J* = 8.5 Hz, 2H), 7.74 (t, *J* = 53.5 Hz, 1H), 7.73 (t, *J* = 7.2 Hz, 1H), 7.43 (td, *J* = 8.7, 2.7 Hz, 1H), 7.38 (dd, *J* = 9.7, 2.7 Hz, 1H), 4.25 (t, *J* = 5.5 Hz, 2H), 4.03 (s, 2H), 3.19 (t, *J* = 5.5 Hz, 2H), 3.15 (d, *J* = 10.5 Hz, 2H), 2.84 (t, *J* = 11.9 Hz, 2H), 2.41–2.33 (m, 2H), 2.22 (d, *J* = 13.3 Hz, 2H).

Synthesis of 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1*H*-pyrazol-1-yl)benzoic Acid (29)

(*Scheme 2*). 1-Cyclopropylethanone (11.8 mL, 119 mmol) was dissolved in toluene (100 mL) and cooled to 0 °C. NaH (60% dispersion, 9.5 g, 238 mmol) was added portionwise and stirred at 0 °C for 30 min. Ethyl 2,2-diethoxyacetate (21 mL, 119 mmol) was added dropwise, and the reaction was stirred at 0 °C for 2 h, after which the reaction was allowed to warm to rt and left to stir for 1 h. The reaction was cooled to 0 °C and H₂O was added dropwise until the reaction was quenched, followed by 3 M HCl solution, dropwise, until the solution was pH 2. NH₄Cl (saturated solution) was added to neutralize, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried over Na₂SO₄ and concentrated *in vacuo* to afford the title compound, which was used in the next step with no further purification.

4-(5-Cyclopropyl-3-formyl-1*H*-pyrazol-1-yl)benzoic Acid (85). 1-Cyclopropyl-4,4-diethoxybutane-1,3-dione (**82**) (995 mg, 4.64 mmol) was dissolved in EtOH (2 mL) and H₂O (2 mL), and 4-hydrazinobenzoic acid (642 mg, 4.22 mmol) was added. The reaction mixture was stirred at 35 °C for 18 h and then allowed to cool to rt and concentrated *in vacuo* to afford an orange solid. The solid was triturated with Et₂O, and the yellow solid filtered and dried to afford 4-(5-cyclopropyl-3-formyl-1*H*-pyrazol-1-yl)benzoic acid (443 mg, 39%). LCMS (ESI) *m/z*: 257 (M + H)⁺. ¹H NMR (500 MHz, *d*⁶-DMSO): δ 13.17 (br s, 1H), 9.92 (s, 1H), 8.16–8.12 (m, 2H), 7.89–7.86 (m, 2H), 6.70 (s, 1H), 1.96–1.89 (m, 1H), 1.04–0.97 (m, 2H), 0.87–0.82 (m, 2H).

4-(5-Cyclopropyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1*H*-pyrazol-1-yl)benzoic Acid (27). Spiro[isochromane-1,4'-piperidine] (10.73 g, 52.80 mmol), 4-(5-cyclopropyl-3-formyl-1*H*-pyrazol-1-yl)benzoic acid (**85**) (12.30 g, 48.00 mmol), and sodium triacetoxyborohydride (20.35 g, 95.99 mmol) were combined in DCM (4 mL) according to General Method 1. After work-up, the crude material was passed through a silica plug (washing with 0–30% MeOH in EtOAc) to afford 4-[5-cyclopropyl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)-1*H*-pyrazol-1-yl]benzoic acid (15.00 g, 70%). LCMS (ESI) *m/z*: 444 (M + H)⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.74 (br s, 1H), 8.09–8.05 (m, 2H), 7.83–7.79 (m, 2H), 7.27–7.06 (m, 4H), 6.17 (s, 1H), 3.82 (t, *J* = 5.4 Hz, 2H), 3.51 (s, 2H), 2.79–2.65 (m, 4H), 2.40 (t, *J* = 11.9 Hz, 2H), 1.98–1.89 (m, 4H), 1.78 (d, *J* = 13.2 Hz, 2H), 1.04–0.99 (m, 2H), 0.80–0.75 (m, 2H).

Synthesis of 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1*H*-pyrazol-1-yl)benzoic Acid (29) Hydrochloride (*Scheme 2*). 4-[5-Cyclopropyl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)-1*H*-pyrazol-1-yl]benzoic acid (**29**) (35 g, 79 mmol) was suspended in MeOH (50 mL) and 4 M HCl in dioxane (49 mL, 197 mmol) was added. The suspended solids went into the solution and the reaction was stirred at rt for 2 h. The precipitated solid was filtered and washed with a small amount of cold MeOH and dried. The solid was then recrystallized from 10% H₂O in EtOH (~1.70 L) to afford the title compound as the HCl salt (17 g, 44%). LCMS (ESI) *m/z*: 444 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₇H₃₀N₃O₃ [M + H]⁺, 444.2287; found, 444.2278. ¹H NMR (400 MHz, DMSO-*d*₆): δ 13.21 (br s, 1H), 10.58 (br s, 1H), 8.14–8.11 (m, 2H), 7.87–7.84 (m, 2H), 7.27–7.12 (m, 4H), 6.48 (s, 1H), 4.38 (s, 2H), 3.87 (t, *J* = 5.3 Hz, 2H), 3.43–3.37 (m, 2H), 3.30–3.20 (m, 2H), 2.78 (t, *J* = 5.3 Hz, 2H), 2.41–2.33 (m, 2H), 2.06–1.95 (m, 3H), 1.08–1.03 (m, 2H), 0.79–0.75 (m, 2H).

Synthesis of 4-(5-Cyclobutyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (30) (Scheme 2). 1-Cyclobutyl-4,4-diethoxybutane-1,3-dione (85). To a solution of 1-cyclobutylethanone (5 g, 51 mmol) in toluene (43 mL) cooled to 0 °C was added NaH (60% dispersion, 4 g, 102 mmol) portionwise. The reaction was stirred at 0 °C for 10 min before the dropwise addition of ethyl 2,2-diethoxyacetate (9.1 mL, 51 mmol). The reaction was stirred at 0 °C for further 10 min before being allowed to warm to rt. After 1 h, the reaction started to exotherm, and the reaction was cooled to 0 °C for an additional 1 h. Water was added dropwise until the reaction was quenched, followed by 3 M HCl until the solution was pH 4. The organics were extracted with DCM, passed through a hydrophobic frit, and concentrated *in vacuo* to afford the title compound, which was used in the next step with no further purification.

4-(5-Cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic Acid (86). 1-Cyclobutyl-4,4-diethoxybutane-1,3-dione (83) (4.80 g, 21.03 mmol) was dissolved in EtOH (2 mL) and H₂O (2 mL), and 4-hydrazinobenzoic acid (3.20 g, 21.03 mmol) were added. The mixture was stirred at 35 °C for 18 and then allowed to cool to rt and concentrated *in vacuo* to afford a mixture of 4-(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid and 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid (5.15 g, 86% total). No attempt was made to separate isomers at this stage, and the mixture was used without further purification. LCMS (ESI) *m/z*: 271 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 11.85 (br s, 1H), 10.04 (s, 1H), 8.29 (d, *J* = 8.6 Hz, 2H), 7.60 (d, *J* = 8.6 Hz, 2H), 6.91 (s, 1H), 3.57 (quint, *J* = 8.6 Hz, 1H), 2.49–1.90 (m, 6H) (desired isomer reported). 4-(5-Cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid and 4-(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid (5.15 g, 19.05 mmol total as a mixture of isomers) were dissolved in *tert*-butanol (20 mL). DMAP (6.99 g, 57.16 mmol) and EDC.HCl (7.31 g, 38.11 mmol) were added. The mixture was heated to reflux for 2 h and then allowed to cool to rt and poured into H₂O. The product was extracted with EtOAc, dried (hydrophobic frit), and concentrated *in vacuo*. The crude material was purified by flash chromatography (0–20% EtOAc in heptane) to afford the transesterified methyl ester, methyl 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoate (641 mg, 12%). LCMS (ESI) *m/z*: 285 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 9.87 (s, 1H), 8.17 (d, *J* = 8.6 Hz, 2H), 7.58 (d, *J* = 8.6 Hz, 2H), 7.02 (s, 1H), 3.66 (quint, *J* = 8.6 Hz, 1H), 2.45–2.37 (m, 2H), 2.32–2.23 (m, 2H), 2.13–2.02 (m, 1H), 2.01–1.91 (m, 1H). Methyl 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoate (641 mg, 2.25 mmol) was dissolved in MeOH, and 2 M NaOH (11.27 mL, 22.55 mmol) was added. The mixture was stirred at rt for 2 h and then neutralized with 3 M HCl and extracted with DCM. The organics were separated, dried (hydrophobic frit), and concentrated *in vacuo* to afford the title compound (632 mg, 100%). LCMS (ESI) *m/z*: 271 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 10.02 (s, 1H), 8.27 (d, *J* = 8.6 Hz, 2H), 7.59 (d, *J* = 8.6 Hz, 2H), 6.89 (s, 1H), 3.56 (quint, *J* = 8.4 Hz, 1H), 2.39–2.29 (m, 2H), 2.19 (quint, *J* = 9.2 Hz, 2H), 2.00 (quint, 9.2 Hz, 1H), 1.98–1.90 (m, 1H).

4-(5-Cyclobutyl-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (30). Spiro[isochromane-1,4'-piperidine] (38 mg, 0.19 mmol), 4-(5-cyclobutyl-3-formyl-1H-pyrazol-1-yl)benzoic acid (86) (50 mg, 0.19 mmol), and sodium triacetoxyborohydride (78 mg, 0.37 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title

compound (16 mg, 18%). LCMS (ESI) *m/z*: 458 (M + H)⁺. HRMS (ESI) *m/z*: calcd for C₂₈H₃₂N₃O₃ [M + H]⁺, 458.2433; found, 458.2438. ¹H NMR (500 MHz, CDCl₃): δ 8.03 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 7.8 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 7.18 (td, *J* = 7.3, 1.3 Hz, 1H), 6.40 (s, 1H), 4.01 (s, 2H), 3.93 (t, *J* = 5.5 Hz, 2H), 3.52–3.44 (m, 3H), 3.00 (t, *J* = 12.2 Hz, 2H), 2.85 (t, *J* = 5.4 Hz, 2H), 2.60 (t, *J* = 13.7 Hz, 2H), 2.28–1.89 (m, 2H), 2.13–1.99 (m, 2H), 1.95–1.86 (m, 1H), 1.86–1.77 (m, 1H).

Synthesis of 4-(5-Methoxy-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (31) (Scheme 3). Methyl 1-(4-Bromophenyl)-5-hydroxy-1H-pyrazole-3-carboxylate (110). Dimethyl but-2-ynedioate (61) (3.29 mL, 26.73 mmol) was dissolved in Et₂O (50 mL), and a suspension of 4-bromophenylhydrazine (5.00 g, 26.73 mmol) in Et₂O (50 mL) was added slowly over 30 min. The reaction mixture was stirred at rt for 1 h and then concentrated *in vacuo*. The residue was redissolved in MeOH (100 mL), NaOMe (25% wt) (23 mL, 106.93 mmol) was added, and the reaction mixture was stirred at rt for 18 h. The mixture was concentrated *in vacuo*, and then 6 M HCl (10 mL) was added. The resulting precipitate was filtered and washed with DCM and Et₂O. The solid was redissolved in MeOH, 10 drops of H₂SO₄ were added, and the mixture was heated to reflux for 4 h and then allowed to cool to rt. The resulting precipitate was filtered and washed with ice-cold MeOH and air-dried to afford the title compound (5.65 g, 64%). LCMS (ESI) *m/z*: 297/299 (M + H)⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.46 (br s, 1H), 7.76–7.67 (m, 4H), 5.99 (s, 1H), 3.37 (br s, 1H).

Methyl 1-(4-Bromophenyl)-5-methoxy-1H-pyrazole-3-carboxylate (114). Methyl 1-(4-bromophenyl)-5-hydroxy-1H-pyrazole-3-carboxylate (110) (250 mg, 0.84 mmol) was dissolved in DMF (5 mL) and K₂CO₃ (174 mg, 1.26 mmol) was added. The reaction mixture was cooled to 0 °C, and iodomethane (0.06 mL, 0.93 mmol) was added dropwise. The reaction was allowed to warm to rt and stirred at this temperature for 2 h. EtOAc and H₂O were added, and the organics were separated and washed with H₂O, NaHCO₃ (saturated solution), and brine before concentrating *in vacuo*. The crude material was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound (162 mg, 62%). LCMS (ESI) *m/z*: 311/313 (M + H)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 8.9 Hz, 2H), 7.56 (d, *J* = 8.9 Hz, 2H), 6.23 (s, 1H), 3.99 (s, 3H), 3.94 (s, 3H).

1-(4-Bromophenyl)-5-methoxy-1H-pyrazole-3-carbaldehyde (118). Methyl 1-(4-bromophenyl)-5-methoxy-1H-pyrazole-3-carboxylate (114) (162 mg, 0.52 mmol) and DIBAL (1 M in DCM) (0.52 mL, 0.52 mmol) were combined in THF (5 mL) according to General Method 5b. Further DIBAL (1 M in DCM) (0.52 mL, 0.52 mmol) was added in this case to push the reaction to completion. MnO₂ (453 mg, 5.21 mmol) was added in the second step according to General Method 5b. Work-up and purification afforded the title compound (146 mg, 100%). LCMS (ESI) *m/z*: 281/283 (M + H)⁺. ¹H NMR (500 MHz, CDCl₃): δ 9.88 (s, 1H), 7.66 (d, *J* = 9.0 Hz, 2H), 7.60 (d, *J* = 9.0 Hz, 2H), 6.18 (s, 1H), 4.00 (s, 3H).

1'-((1-(4-Bromophenyl)-5-methoxy-1H-pyrazol-3-yl)-methyl)spiro[isochromane-1,4'-piperidine] (122). Spiro[isochromane-1,4'-piperidine] (181 mg, 0.89 mmol), 1-(4-bromophenyl)-5-methoxy-1H-pyrazole-3-carbaldehyde (118) (250 mg, 0.89 mmol), and sodium triacetoxyborohydride (377 mg, 1.78 mmol) were combined in DCM (5 mL) according to General Method 1. Work-up and purification

afforded the title compound (287 mg, 68%). LCMS (ESI) m/z : 468/470 ($M + H$)⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.61 (d, $J = 8.9$ Hz, 2H), 7.52 (d, $J = 8.9$ Hz, 2H), 7.24–7.18 (m, 2H), 7.17–7.13 (m, 1H), 7.08 (s, $J = 7.4$ Hz, 1H), 5.85 (s, 1H), 3.96 (s, 3H), 3.88 (t, $J = 5.5$ Hz, 2H), 3.81–3.70 (m, 2H), 3.08–2.96 (m, 2H), 2.82 (t, $J = 5.5$ Hz, 2H), 2.77–2.65 (m, 2H), 2.31–2.14 (m, 2H), 1.94 (d, $J = 13.8$ Hz, 2H).

4-(5-Methoxy-3-(spiro[isochromane-1,4'-piperidin]-1'-yl-methyl)-1H-pyrazol-1-yl)benzoic Acid (31). 1'-[[1-(4-Bromophenyl)-5-methoxy-1H-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (**122**) (58 mg, 0.12 mmol), *N*-formylsaccharin (31 mg, 0.15 mL), Pd(OAc)₂ (0.8 mg, 0.004 mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31 mmol) were combined in DMF (1 mL) according to General Method 5. Work-up and purification afforded the title compound (11 mg, 21%). LCMS (ESI) m/z : 434 ($M + H$)⁺. HRMS (ESI) m/z : calcd for C₂₅H₂₈N₃O₄ [$M + H$]⁺, 434.2080; found, 434.2077. ¹H NMR (400 MHz, CDCl₃): δ 8.05 (d, $J = 8.6$ Hz, 2H), 7.67 (d, $J = 8.6$ Hz, 2H), 7.23 (d, $J = 7.9$ Hz, 1H), 7.21–7.11 (m, 2H), 7.08 (d, $J = 7.4$ Hz, 1H), 5.85 (s, 1H), 3.94–3.88 (m, 7H), 3.35 (d, $J = 10.8$ Hz, 2H), 2.92 (t, $J = 11.9$ Hz, 2H), 2.84 (t, $J = 5.3$ Hz, 2H), 2.46 (t, $J = 13.0$ Hz, 2H), 2.00 (d, $J = 14.0$ Hz, 2H).

Synthesis of 4-(5-Ethoxy-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (32) (Scheme 3). Methyl 1-(4-bromophenyl)-5-ethoxy-1H-pyrazole-3-carboxylate (**115**). Methyl 1-(4-bromophenyl)-5-hydroxy-1H-pyrazole-3-carboxylate (**110**) (500 mg, 1.68 mmol) was dissolved in DMF (5 mL) and K₂CO₃ (349 mg, 2.52 mmol) was added. The reaction mixture was cooled to 0 °C, and iodoethane (0.13 mL, 1.68 mmol) was added dropwise. The reaction was allowed to warm to rt and stirred for 2 h. EtOAc and H₂O were added. The organics were separated and washed with H₂O, NaHCO₃ (saturated aqueous solution), and brine and concentrated *in vacuo*. The crude material was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound (369 mg, 67%). LCMS (ESI) m/z : 369/371 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.65 (d, $J = 8.9$ Hz, 2H), 7.56 (d, $J = 8.9$ Hz, 2H), 6.20 (s, 1H), 4.22 (q, $J = 7.1$ Hz, 2H), 3.93 (s, 3H), 1.46 (t, $J = 7.1$ Hz, 3H).

1-(4-Bromophenyl)-5-ethoxy-1H-pyrazole-3-carbaldehyde (119). Methyl 1-(4-bromophenyl)-5-ethoxy-1H-pyrazole-3-carboxylate (**115**) (369 mg, 1.13 mmol) and DIBAL (1.36 mL, 1.36 mmol) were combined in THF (5 mL) according to General Method 6b. Further, DIBAL (2.72 mL, 2.72 mmol) was added in this case to push the reaction to completion. MnO₂ (987 mg, 11.45 mmol) was added in the second step according to General Method 6b. Work-up and purification afforded the title compound (164 mg, 47%). LCMS (ESI) m/z : 295/297 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃): δ 9.88 (s, 1H), 7.68 (d, $J = 9.0$ Hz, 2H), 7.60 (d, $J = 9.0$ Hz, 2H), 6.15 (s, 1H), 4.23 (q, $J = 7.1$ Hz, 2H), 1.48 (t, $J = 7.1$ Hz, 2H).

1'-((1-(4-Bromophenyl)-5-ethoxy-1H-pyrazol-3-yl)-methyl)spiro[isochromane-1,4'-piperidine] (123). Spiro[isochromane-1,4'-piperidine] (56 mg, 0.28 mmol), 1-(4-bromophenyl)-5-ethoxy-1H-pyrazole-3-carbaldehyde (**119**) (82 mg, 0.28 mmol), and sodium triacetoxyborohydride (118 mg, 0.56 mmol) were combined in DCM (10 mL) according to General Method 1. Work-up followed by flash chromatography (10–100% EtOAc in heptane) afforded the title compound (96 mg, 72%). LCMS (ESI) m/z : 482/484 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.64 (d, $J = 8.9$ Hz, 2H), 7.51 (d, $J = 8.9$ Hz, 2H), 7.23–7.12 (m, 3H), 7.08 (d, $J = 7.5$ Hz, 1H), 5.76 (s,

1H), 4.18 (q, $J = 7.1$ Hz, 2H), 3.89 (t, $J = 5.5$ Hz, 2H), 3.65 (s, 2H), 2.96–2.87 (m, 2H), 2.82 (t, $J = 5.5$ Hz, 2H), 2.66–2.54 (m, 2H), 2.20–2.07 (m, 2H), 1.91 (d, $J = 14.0$ Hz, 2H), 1.46 (t, $J = 7.1$ Hz, 3H).

4-(5-Ethoxy-3-(spiro[isochromane-1,4'-piperidin]-1'-yl-methyl)-1H-pyrazol-1-yl)benzoic Acid (32). 1'-[[1-(4-Bromophenyl)-5-ethoxy-1H-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (**123**) (96 mg, 0.20 mmol), Pd(OAc)₂ (1 mg, 0.01 mmol), Xantphos (5 mg, 0.01 mmol), KF (29 mg, 0.50 mmol), and *N*-formylsaccharin (50 mg, 0.24 mmol) were combined in DMF (1 mL) according to General Method 5. Work-up and purification afforded the title compound (10 mg, 11%). LCMS (ESI) m/z : 448 ($M + H$)⁺. HRMS (ESI) m/z : calcd for C₂₆H₃₀N₃O₄ [$M + H$]⁺: 448.2236; found, 448.2249. ¹H NMR (400 MHz, CDCl₃): δ 8.07 (d, $J = 8.6$ Hz, 2H), 7.70 (d, $J = 8.6$ Hz, 2H), 7.25–7.21 (m, 1H), 7.20–7.11 (m, 2H), 7.08 (d, $J = 7.5$ Hz, 1H), 5.84 (s, 1H), 4.11 (q, $J = 7.1$ Hz, 2H), 3.94–3.88 (m, 2H), 3.33 (d, $J = 10.4$ Hz, 2H), 2.92 (t, $J = 12.1$ Hz, 2H), 2.84 (t, $J = 5.5$ Hz, 2H), 2.45 (t, $J = 13.4$ Hz, 2H), 2.00 (d, $J = 14.0$ Hz, 2H), 1.41 (t, $J = 7.1$ Hz, 3H).

Synthesis of 4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)pyrazol-1-yl]benzoic Acid (33) (Scheme 3). Methyl 1-(4-bromophenyl)-5-chloro-4-formyl-1H-pyrazole-3-carboxylate (**111**). POCl₃ (2 mL, 1.68 mmol) was added cautiously to methyl 1-(4-bromophenyl)-5-hydroxy-pyrazole-3-carboxylate (**120**) (500 mg, 1.68 mmol), and then DMF (0.16 mL, 2.02 mmol) was added. The reaction mixture was heated to 100 °C for 2 h and then allowed to cool to rt, added to a H₂O/ice mixture, and stirred for 1 h. The resulting precipitate was filtered, washed with H₂O and heptane, and air-dried. The solid was dissolved in DCM and passed through a hydrophobic frit. The filtrate was concentrated *in vacuo* to afford the title compound as a beige solid (450 mg, 70%). ¹H NMR (400 MHz, CDCl₃): δ 10.54 (s, 1H), 7.72–7.69 (m, 2H), 7.49–7.46 (m, 2H), 4.05 (s, 3H).

Methyl 1-(4-Bromophenyl)-4-formyl-5-(pyrrolidin-1-yl)-1H-pyrazole-3-carboxylate (112). Methyl 1-(4-bromophenyl)-5-chloro-4-formyl-pyrazole-3-carboxylate (**111**) (600 mg, 1.75 mmol) and pyrrolidine (248 mg, 3.49 mmol) were taken up in DMF (3 mL) before the addition of K₂CO₃ (483 mg, 3.49 mmol). The reaction mixture was heated to 120 °C in the microwave for 1 h and then quenched with water. The product was extracted with DCM, dried (hydrophobic frit), and concentrated *in vacuo*. The crude material was purified by flash chromatography (0–80% EtOAc in heptane) to afford the title compound (270 mg, 39%). LCMS (ESI) m/z : 378, 380 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃): δ 10.37 (s, 1H), 7.62–7.58 (m, 2H), 7.38–7.45 (m, 2H), 3.97 (s, 3H), 3.26–3.22 (m, 4H), 1.89–1.86 (m, 4H).

Methyl 1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1H-pyrazole-3-carboxylate (116). To a solution of *p*-TsOH (24 mg, 0.13 mmol) in MeOH (3 mL) was added methyl 1-(4-bromophenyl)-4-formyl-5-pyrrolidin-1-yl-pyrazole-3-carboxylate (**112**) (220 mg, 0.58 mmol). The reaction mixture was heated to 120 °C in the microwave for 1 h. The reaction was concentrated *in vacuo* to afford the title compound, which was used in the next step with no further purification (200 mg, 77%). LCMS (ESI) m/z : 350, 352 ($M + H$)⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.59–7.50 (m, 4H), 6.21 (s, 1H), 3.92 (s, 3H), 3.00 (m, 4H), 1.88–1.85 (m, 4H).

1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1H-pyrazole-3-carbaldehyde (120). Methyl 1-(4-bromophenyl)-5-pyrrolidin-1-yl-pyrazole-3-carboxylate (**116**) (200 mg, 0.57 mmol) was

dissolved in DCM (10 mL) and cooled to $-78\text{ }^{\circ}\text{C}$ under N_2 . DIBAL (1 M in DCM, 1.43 mL, 1.43 mmol) was then added dropwise over 20 min and the reaction was stirred for a further 1 h at $-78\text{ }^{\circ}\text{C}$. The reaction was quenched with 5 mL of 1:1 MeOH/ H_2O , allowed to warm up to rt, and then passed through a hydrophobic frit and concentrated *in vacuo* to the title compound, which was used in the next step with no further purification (166 mg, 81%). LCMS (ESI) m/z : 320, 322 ($\text{M} + \text{H}^+$). ^1H NMR (400 MHz, CDCl_3): δ 9.87 (s, 1H), 7.63–7.59 (m, 2H), 7.56–7.53 (m, 2H), 6.15 (s, 1H), 3.00 (m, 4H), 1.89–1.86 (m, 4H).

1'-[[1-(4-Bromophenyl)-5-pyrrolidin-1-yl-pyrazol-3-yl]-methyl]spiro[isochromane-1,4'-piperidine] (124). Spiro[isochromane-1,4'-piperidine] (50 mg, 0.25 mmol), 1-(4-bromophenyl)-5-pyrrolidin-1-yl-1H-pyrazole-3-carbaldehyde (120) (88 mg, 0.25 mmol), and sodium triacetoxyborohydride (104 mg, 0.49 mmol) were combined in DCM (3 mL) according to General Method 1. Work-up followed by purification afforded the title compound (62 mg, 47%). HRMS (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{32}\text{BrN}_4\text{O}$ [$\text{M} + \text{H}^+$]: 509.1670; found, 509.1756. ^1H NMR (400 MHz, CHCl_3): δ 7.54–7.53 (m, 4H), 7.24–7.08 (m, 4H), 5.75 (s, 1H), 3.91 (t, $J = 5.5$ Hz, 2H), 3.58 (s, 2H), 3.00 (t, $J = 6.6$ Hz, 4H), 2.89–2.81 (m, 4H), 2.56–2.48 (m, 2H), 2.14–2.01 (m, 2H), 1.93–1.84 (m, 6H).

4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-1,4'-piperidine]-1'-ylmethyl)pyrazol-1-yl]benzoic Acid (33). 1'-[[1-(4-Bromophenyl)-5-pyrrolidin-1-yl-1H-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (124) (62 mg, 0.12 mmol), *N*-formylsaccharin (31 mg, 0.15 mmol), $\text{Pd}(\text{OAc})_2$ (0.8 mg, 0.004 mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31 mmol) were combined in DMF (2 mL) according to General Method 5. Work-up and purification afforded the title compound (4 mg, 6%). HRMS (ESI) m/z : calcd for $\text{C}_{28}\text{H}_{33}\text{N}_4\text{O}_3$ [$\text{M} + \text{H}^+$]: 473.2547; found, 473.2545. ^1H NMR (400 MHz, $\text{D}_6\text{-DMSO}$): δ 8.02 (d, $J = 8.8$ Hz, 2H), 7.71 (d, $J = 8.7$ Hz, 2H), 7.22–7.07 (m, 4H), 5.83 (s, 1H), 3.81 (dd, $J = 5.5, 5.5$ Hz, 2H), 3.44 (s, 2H), 3.33 (s, 1H), 2.96 (dd, $J = 6.4, 6.4$ Hz, 4H), 2.73 (dd, $J = 5.4, 5.4$ Hz, 4H), 2.42–2.33 (m, 2H), 1.97–1.89 (m, 2H), 1.84–1.76 (m, 6H).

Synthesis of 4-(5-Morpholino-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (34) (Scheme 3). Methyl 1-(4-bromophenyl)-4-formyl-5-morpholino-1H-pyrazole-3-carboxylate (113). Methyl 1-(4-bromophenyl)-5-chloro-4-formyl-1H-pyrazole-3-carboxylate (111) (100 mg, 0.29 mmol) and K_2CO_3 (80 mg, 0.58 mmol) were mixed in DMF (1 mL) and morpholine (0.05 mL, 0.58 mmol) was added. The reaction mixture was heated to $120\text{ }^{\circ}\text{C}$ in the microwave for 1 h and then quenched with H_2O and extracted with DCM. The organics were concentrated *in vacuo*, and the crude material was purified by flash chromatography (0–80% EtOAc in heptane) to afford the title compound (37 mg, 31%). ^1H NMR (400 MHz, CDCl_3): δ 10.44 (s, 1H), 7.66 (d, $J = 8.8$ Hz, 2H), 7.42 (d, $J = 8.7$ Hz, 2H), 3.99 (s, 3H), 3.73–3.69 (m, 4H), 3.11 (dd, $J = 4.6, 4.6$ Hz, 4H).

Methyl 1-(4-Bromophenyl)-5-morpholino-1H-pyrazole-3-carboxylate (117). Methyl 1-(4-bromophenyl)-4-formyl-5-morpholino-1H-pyrazole-3-carboxylate (113) (250 mg, 0.63 mmol) was mixed in MeOH (5 mL) and *p*-TsOH (24 mg, 0.13 mmol) was added. The reaction mixture was heated to $120\text{ }^{\circ}\text{C}$ in the microwave for 1 h and then concentrated *in vacuo* to afford the title compound (200 mg, 78%). ^1H NMR (400 MHz, CDCl_3): δ 7.73 (2H, d, $J = 8.8$ Hz), 7.61 (2H, d, $J = 8.9$ Hz),

6.47 (1H, s), 3.95 (3H, s), 3.77–3.73 (4H, m), 2.92–2.89 (4H, m).

1-(4-Bromophenyl)-5-morpholino-1H-pyrazole-3-carbaldehyde (121). Methyl 1-(4-bromophenyl)-5-morpholino-1H-pyrazole-3-carboxylate (117) (275 mg, 0.75 mmol) and DIBAL (1 M in DCM) (1.88 mL, 1.88 mmol) were combined in DCM (5 mL) according to General Method 6a. Work-up afforded the title compound, which was used in the next step without further purification. ^1H NMR (400 MHz, CDCl_3): δ 9.93 (1H, s), 7.78–7.56 (4H, m), 6.42 (1H, s), 3.78–3.74 (4H, m), 2.93–2.88 (4H, m). Used crude—contaminated with the benzyl alcohol.

1'-((1-(4-Bromophenyl)-5-morpholino-1H-pyrazol-3-yl)-methyl)spiro[isochromane-1,4'-piperidine] (125). Spiro[isochromane-1,4'-piperidine] (78 mg, 0.38 mmol), 1-(4-bromophenyl)-5-morpholino-1H-pyrazole-3-carbaldehyde (121) (215 mg, 0.38 mmol), and sodium triacetoxyborohydride (163 mg, 0.77 mmol) were combined in DCM (5 mL) according to General Method 1. Work-up and purification afforded the title compound (200 mg, 95%). ^1H NMR (400 MHz, CDCl_3): δ 7.76 (d, $J = 8.8$ Hz, 2H), 7.56 (d, $J = 8.8$ Hz, 2H), 7.24–7.10 (m, 4H), 5.97 (s, 1H), 3.92 (m, 2H), 3.78–3.75 (m, 4H), 3.61 (s, 2H), 2.93–2.83 (m, 8H), 2.57–2.50 (m, 2H), 2.15–2.03 (m, 2H), 1.93 (d, $J = 12.5$ Hz, 2H).

4-(5-Morpholino-3-(spiro[isochromane-1,4'-piperidin]-1'-ylmethyl)-1H-pyrazol-1-yl)benzoic Acid (34). 1'-[[1-(4-Bromophenyl)-5-morpholino-1H-pyrazol-3-yl]methyl]spiro[isochromane-1,4'-piperidine] (125) (150 mg, 0.29 mmol), $\text{Pd}(\text{OAc})_2$ (2 mg, 0.01 mmol), Xantphos (7 mg, 0.01 mmol), KF (42 mg, 0.72 mmol), and *N*-formylsaccharin (73 mg, 0.34 mmol) were combined in DMF (2 mL) according to General Method 5. Work-up and purification afforded the title compound (8 mg, 5%). HRMS (ESI) m/z : calcd for $\text{C}_{28}\text{H}_{33}\text{N}_4\text{O}_4$ [$\text{M} + \text{H}^+$], 498.2502; found, 489.2498. ^1H NMR (400 MHz, $\text{D}_6\text{-DMSO}$): δ 8.05–7.95 (m, 4H), 7.23–7.08 (m, 4H), 6.05 (s, 1H), 3.82 (dd, $J = 5.4, 5.4$ Hz, 2H), 3.70 (dd, $J = 4.5, 4.5$ Hz, 4H), 3.46 (s, 2H), 2.84 (dd, $J = 4.5, 4.5$ Hz, 4H), 2.75–2.71 (m, 4H), 2.41–2.33 (m, 2H), 1.97–1.90 (m, 2H), 1.78 (d, $J = 12.7$ Hz, 2H).

Synthesis of 4-(5-Cyclopropyl-3-((6-fluorospiro[isochromane-1,4'-piperidin]-1'-yl)methyl)-1H-pyrazol-1-yl)benzoic Acid (35) (Scheme 2). **4-(5-Cyclopropyl-3-((6-fluorospiro[isochromane-1,4'-piperidin]-1'-yl)methyl)-1H-pyrazol-1-yl)benzoic Acid (35)**. 6-Fluorospiro[isochromane-1,4'-piperidine] (50) (216 mg, 0.98 mmol), 4-(5-cyclopropyl-3-formyl-1H-pyrazol-1-yl)benzoic acid (85) (250 mg, 0.98 mmol), and sodium triacetoxyborohydride (414 mg, 1.95 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (261 mg, 57%). LCMS (ESI) m/z : 462 ($\text{M} + \text{H}^+$). HRMS (ESI) m/z : calcd for $\text{C}_{27}\text{H}_{29}\text{FN}_3\text{O}_3$ [$\text{M} + \text{H}^+$], 462.2193; found, 462.2220. ^1H NMR (500 MHz, CDCl_3): δ 8.07 (d, $J = 8.5$ Hz, 2H), 7.52 (d, $J = 8.5$ Hz, 2H), 7.25 (dd, $J = 8.7, 5.5$ Hz, 1H), 6.87 (td, $J = 8.7, 2.7$ Hz, 1H), 6.78 (dd, $J = 9.2, 2.7$ Hz, 1H), 6.06 (s, 1H), 3.97 (s, 2H), 3.90 (t, $J = 5.5$ Hz, 2H), 3.41 (d, $J = 10.7$ Hz, 2H), 2.94 (t, $J = 12.2$ Hz, 2H), 2.85–2.79 (m, 2H), 2.54 (td, $J = 13.9, 4.0$ Hz, 2H), 1.99 (d, $J = 13.9$ Hz, 2H), 1.86–1.78 (m, 1H), 0.99–0.93 (m, 2H), 0.74–0.69 (m, 2H).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.0c05589>.

Metabolite identification methodologies, chromatograms, proposed metabolite structures, chemistry scheme, PAINS alert analysis and representative compound HPLC UV traces (PDF)

Molecular strings (CSV)

■ AUTHOR INFORMATION

Corresponding Authors

Simon R. Green – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.; orcid.org/0000-0001-5054-4792; Email: s.r.green@dundee.ac.uk

Paul G. Wyatt – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.; orcid.org/0000-0002-0397-245X; Email: P.G.Wyatt@dundee.ac.uk

Tanya Parish – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States; orcid.org/0000-0001-7507-0423; Email: Tanya.parish@seattlechildrens.org

Authors

Peter C. Ray – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Margaret Huggett – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Penelope A. Turner – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Malcolm Taylor – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Laura A. T. Cleghorn – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Julie Early – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Anuradha Kumar – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Shilah A. Bonnett – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Lindsay Flint – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Douglas Joerss – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

James Johnson – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Aaron Korkegian – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Steven Mullen – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Abraham L. Moure – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Susan H. Davis – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Dinakaran Murugesan – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Michael Mathieson – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Nicola Caldwell – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Curtis A. Engelhart – Department of Microbiology and Immunology, Weill Cornell Medical College, New York 10065, United States

Dirk Schnappinger – Department of Microbiology and Immunology, Weill Cornell Medical College, New York 10065, United States

Ola Epemolu – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Fabio Zuccotto – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Jennifer Riley – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Paul Scullion – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Lasto Stojanovski – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Lisa Massoudi – Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado 80523-1682, United States

Gregory T. Robertson – Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado 80523-1682, United States

Anne J. Lenaerts – Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado 80523-1682, United States

Gail Freiberg – AbbVie, North Chicago, Illinois 60064, United States

Dale J. Kempf – AbbVie, North Chicago, Illinois 60064, United States; orcid.org/0000-0002-1408-9099

Thierry Masquelin – Discovery Chemistry Research, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

Philip A. Hipskind – Lgenia Inc., Fortville, Indiana 46040, United States

Joshua Odingo – TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington 98102, United States

Kevin D. Read – Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.; orcid.org/0000-0002-8536-0130

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acsomega.0c05589>

Author Contributions

P.C.R., M.H., and P.A.T. contributed equally to medicinal chemistry design and planning. M.H., P.A.T., M.T., L.A.T.C.,

A.L.M., S.H.D., D.M., M.M., and N.C. contributed to molecule synthesis. J.E., A.K., S.A.B., L.F., D.J., J.J., A.K., S.M., C.A.E., D.S., L.M., G.T.R., A.J.L., S.R.G., and T.P. planned/executed biology studies. O.E., J.R., P.S., L.S., G.F., D.J.K., and K.D.R. planned/executed DMPK/safety studies. P.C.R., M.H., P.A.T., J.E., A.K., O.E., F.Z., T.M., P.A.H., J.O., S.R.G., P.G.W., and T.P. contributed to monthly project planning meetings. P.C.R., P.A. T., M.T., L.A.T.C., and S.R.G. wrote draft manuscript. A.K., C.A.E., D.S., G.T.R., A.J.L., D.J.K., T.M., P.A.H., K.D.R., P.G.W., and T.P. edited the manuscript

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Lucy Ellis, Fred Simeons, Yoko Shishikura, Liam Ferguson, Lorna Campbell, James Roberts, Susan Lawrie, Alex Cookson, Kirsty Cookson, Emma Gutcher, Desiree Zeller, James Ahn, Torey Alling, Lena Anoshchenko, Bryan Grogan, Megha Gupta, Junitta Guzman, Yulia Ovechkina, David Roberts, Catherine Shelton, Bjorn Sunde, Dean Thompson, and Anisa Tracy for technical assistance. This work was funded in part by an award to P.G.W. from the Bill and Melinda Gates Foundation (OPP1066891) and Wellcome Trust (100195/Z/12/Z); by awards from BMG&F to T.P. (OPP1024038) and A.J.L./G.T.R. (OPP1126594); by Eli Lilly and Company in support of the mission of the Lilly TB Drug Discovery Initiative; and an award to T.P. by NIAID of the National Institutes of Health (R01AI099188). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

- (1) Gordon, S. V.; Parish, T. Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe. *Microbiology* **2018**, *164*, 437–439.
- (2) WHO. *Global Tuberculosis Report 2020*; World Health Organization: Geneva (Switzerland), 2020; ISBN 978-92-4-001313-1.
- (3) Zumla, A.; George, A.; Sharma, V.; Herbert, R. H. N.; Oxley, A.; Oliver, M.; Oliver, M. The WHO 2014 Global tuberculosis report-further to go. *Lancet Global Health* **2015**, *3*, E10–E12.
- (4) Dheda, K.; Barry, C. E.; Maartens, G. Tuberculosis. *Lancet* **2016**, *387*, 1211–1226.
- (5) Horsburgh, C. R., Jr.; Barry, C. E., 3rd; Lange, C. Treatment of Tuberculosis. *N. Engl. J. Med.* **2015**, *373*, 2149–2160.
- (6) Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis. *Nature* **2011**, *469*, 483–490.
- (7) Lechartier, B.; Rybniker, J.; Zumla, A.; Cole, S. T. Tuberculosis drug discovery in the post-post-genomic era. *EMBO Mol. Med.* **2014**, *6*, 158–168.
- (8) Kana, B. D.; Karakousis, P. C.; Parish, T.; Dick, T. Future target-based drug discovery for tuberculosis? *Tuberculosis* **2014**, *94*, 551–556.
- (9) Manjunatha, U. H.; Smith, P. W. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. *Bioorg. Med. Chem.* **2015**, *23*, 5087–5097.
- (10) Zuniga, E. S.; Early, J.; Parish, T. The future for early-stage tuberculosis drug discovery. *Future Microbiol.* **2015**, *10*, 217–229.
- (11) Goldman, R. C. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? *Tuberculosis* **2013**, *93*, 569–588.
- (12) Mdululi, K.; Kaneko, T.; Upton, A. The tuberculosis drug discovery and development pipeline and emerging drug targets. *Cold Spring Harbor Perspect. Med.* **2015**, *5*, a021154.
- (13) Li, W.; Upadhyay, A.; Fontes, F. L.; North, E. J.; Wang, Y.; Crans, D. C.; Grzegorzewicz, A. E.; Jones, V.; Franzblau, S. G.; Lee, R. E.; Crick, D. C.; Jackson, M. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. *Antimicrob. Agents Chemother.* **2014**, *58*, 6413–6423.
- (14) Poce, G.; Consalvi, S.; Biava, M. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. *Mini-Rev. Med. Chem.* **2016**, *16*, 1274–1283.
- (15) Sacksteder, K. A.; Protopopova, M.; Barry, C. E., 3rd; Andries, K.; Nacy, C. A. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. *Future Microbiol.* **2012**, *7*, 823–837.
- (16) La Rosa, V.; Poce, G.; Canseco, J. O.; Buroni, S.; Pasca, M. R.; Biava, M.; Raju, R. M.; Porretta, G. C.; Alfonso, S.; Battilocchio, C.; Javid, B.; Sorrentino, F.; Ioerger, T. R.; Sacchetti, J. C.; Manetti, F.; Botta, M.; De Logu, A.; Rubin, E. J.; De Rossi, E. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. *Antimicrob. Agents Chemother.* **2012**, *56*, 324–331.
- (17) Poce, G.; Bates, R. H.; Alfonso, S.; Cocozza, M.; Porretta, G. C.; Ballell, L.; Rullas, J.; Ortega, F.; De Logu, A.; Agus, E.; La Rosa, V.; Pasca, M. R.; De Rossi, E.; Wae, B.; Franzblau, S. G.; Manetti, F.; Botta, M.; Biava, M. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. *PLoS One* **2013**, *8*, e56980.
- (18) Stanley, S. A.; Grant, S. S.; Kawate, T.; Iwase, N.; Shimizu, M.; Wivagg, C.; Silvis, M.; Kazyanskaya, E.; Aquadro, J.; Golas, A.; Fitzgerald, M.; Dai, H.; Zhang, L.; Hung, D. T. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. *ACS Chem. Biol.* **2012**, *7*, 1377–1384.
- (19) Remuñán, M. J.; Pérez-Herrán, E.; Rullas, J.; Alemparte, C.; Martínez-Hoyos, M.; Dow, D. J.; Afari, J.; Mehta, N.; Esquivias, J.; Jiménez, E.; Ortega-Muro, F.; Fraile-Gabaldón, M. T.; Spivey, V. L.; Loman, N. J.; Pallen, M. J.; Constantinidou, C.; Minick, D. J.; Cacho, M.; Rebollo-López, M. J.; González, C.; Sousa, V.; Angulo-Barturen, I.; Mendoza-Losana, A.; Barros, D.; Besra, G. S.; Ballell, L.; Cammack, N. Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. *PLoS One* **2013**, *8*, e60933.
- (20) Kondreddi, R. R.; Jiricek, J.; Rao, S. P. S.; Lakshminarayana, S. B.; Camacho, L. R.; Rao, R.; Herve, M.; Bifani, P.; Ma, N. L.; Kuhne, K.; Goh, A.; Chatterjee, A. K.; Dick, T.; Diagona, T. T.; Manjunatha, U. H.; Smith, P. W. Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. *J. Med. Chem.* **2013**, *56*, 8849–8859.
- (21) Lun, S.; Guo, H.; Onajole, O. K.; Pieroni, M.; Gunosewoyo, H.; Chen, G.; Tipparaju, S. K.; Ammerman, N. C.; Kozikowski, A. P.; Bishai, W. R. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. *Nat. Commun.* **2013**, *4*, 2907.
- (22) Grzegorzewicz, A. E.; Pham, H.; Gundi, V. A. K. B.; Scherman, M. S.; North, E. J.; Hess, T.; Jones, V.; Gruppo, V.; Born, S. E. M.; Korduláková, J.; Chavadi, S. S.; Morisseau, C.; Lenaerts, A. J.; Lee, R. E.; McNeil, M. R.; Jackson, M. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. *Nat. Chem. Biol.* **2012**, *8*, 334–341.
- (23) Zheng, H.; Williams, J. T.; Coulson, G. B.; Haiderer, E. R.; Abramovitch, R. B. HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter. *Antimicrob. Agents Chemother.* **2018**, *62*, e02459.
- (24) Raynaud, C.; Daher, W.; Johansen, M. D.; Roquet-Banères, F.; Blaise, M.; Onajole, O. K.; Kozikowski, A. P.; Herrmann, J.-L.; Dziadek, J.; Gobis, K.; Kremer, L. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus. *ACS Infect. Dis.* **2020**, *6*, 324–337.
- (25) Dal Molin, M.; Selchow, P.; Schäfle, D.; Tschumi, A.; Ryckmans, T.; Laage-Witt, S.; Sander, P. Identification of novel scaffolds targeting Mycobacterium tuberculosis. *J. Mol. Med.* **2019**, *97*, 1601–1613.
- (26) Poce, G.; Consalvi, S.; Venditti, G.; Alfonso, S.; Desideri, N.; Fernandez-Menendez, R.; Bates, R. H.; Ballell, L.; Barros Aguirre, D.; Rullas, J.; De Logu, A.; Gardner, M.; Ioerger, T. R.; Rubin, E. J.; Biava,

M. Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis. *ACS Med. Chem. Lett.* **2019**, *10*, 1423–1429.

(27) Dupont, C.; Chen, Y.; Xu, Z.; Roquet-Banères, F.; Blaise, M.; Witt, A.-K.; Dubar, F.; Biot, C.; Guérardel, Y.; Maurer, F. P.; Chng, S.-S.; Kremer, L. A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3. *J. Biol. Chem.* **2019**, *294*, 17512–17523.

(28) Williams, J. T.; Haiderer, E. R.; Coulson, G. B.; Conner, K. N.; Ellsworth, E.; Chen, C.; Alvarez-Cabrera, N.; Li, W.; Jackson, M.; Dick, T.; Abramovitch, R. B. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance. *Antimicrob. Agents Chemother.* **2019**, *63*, e00547.

(29) Korycka-Machala, M.; Viljoen, A.; Pawelczyk, J.; Borowka, P.; Dziadek, B.; Gobis, K.; Brzostek, A.; Kawka, M.; Blaise, M.; Strapagiel, D.; Kremer, L.; Dziadek, J. 1H-Benzodimidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis. *Antimicrob. Agents Chemother.* **2019**, *63*, e00441.

(30) Guardia, A.; Baiget, J.; Cacho, M.; Pérez, A.; Ortega-Guerra, M.; Nxumalo, W.; Khanye, S. D.; Rullas, J.; Ortega, F.; Jiménez, E.; Pérez-Herrán, E.; Fraile-Gabaldón, M. T.; Esquivias, J.; Fernandez, R.; Fernández, E.; Encinas, L.; Alonso, M.; Giordano, I.; Rivero, C.; Miguel-Siles, J.; Osende, J. G.; Badiola, K. A.; Rutledge, P. J.; Todd, M. H.; Remuiñán, M.; Alemparte, C. Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis. *J. Med. Chem.* **2018**, *61*, 11327–11340.

(31) Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. *Drug Discovery Today* **2010**, *15*, 648–655.

(32) Bayliss, M. K.; Butler, J.; Feldman, P. L.; Green, D. V. S.; Leeson, P. D.; Palovich, M. R.; Taylor, A. J. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. *Drug Discovery Today* **2016**, *21*, 1719–1727.

(33) Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. *Nat. Rev. Drug Discovery* **2007**, *6*, 881–890.

(34) Leeson, P. D.; Young, R. J. Molecular Property Design: Does Everyone Get It? *ACS Med. Chem. Lett.* **2015**, *6*, 722–725.

(35) Young, R. J.; Green, D. V. S.; Luscombe, C. N.; Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. *Drug Discovery Today* **2011**, *16*, 822–830.

(36) Miller, M. M.; Liu, Y.; Jiang, J.; Johnson, J. A.; Kamau, M.; Nirschl, D. S.; Wang, Y.; Harikrishnan, L.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Seethala, R.; Peterson, T. L.; Zvyaga, T.; Zhang, J.; Huang, C. S.; Wexler, R. R.; Poss, M. A.; Michael Lawrence, R.; Adam, L. P.; Salvati, M. E. Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6503–6508.

(37) Bonn, B.; Masimirembwa, C. M.; Castagnoli, N., Jr. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. *Drug Metab. Dispos.* **2010**, *38*, 187–199.

(38) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. *J. Med. Chem.* **2006**, *49*, 5029–5046.

(39) Badiola, K. A.; Quan, D. H.; Triccas, J. A.; Todd, M. H. Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science. *PLoS One* **2014**, *9*, e111782.

(40) Ueda, T.; Konishi, H.; Manabe, K. Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives. *Org. Lett.* **2013**, *15*, 5370–5373.

(41) Ollinger, J.; Bailey, M. A.; Moraski, G. C.; Casey, A.; Florio, S.; Alling, T.; Miller, M. J.; Parish, T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. *PLoS One* **2013**, *8*, e60531.

(42) Bridal, T. R.; Margulis, M.; Wang, X.; Donio, M.; Sorota, S. Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux. *Assay Drug Dev. Technol.* **2010**, *8*, 755–765.

(43) Bowes, J.; Brown, A. J.; Hamon, J.; Jarolimek, W.; Sridhar, A.; Waldron, G.; Whitebread, S. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. *Nat. Rev. Drug Discovery* **2012**, *11*, 909–922.

(44) Lenaerts, A. J.; Gruppo, V.; Marietta, K. S.; Johnson, C. M.; Driscoll, D. K.; Tompkins, N. M.; Rose, J. D.; Reynolds, R. C.; Orme, I. M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. *Antimicrob. Agents Chemother.* **2005**, *49*, 2294–2301.